<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1003257032
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RESPAL ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        RISPERIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        103.7
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AX08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Respal belongs to a group of medicines called &lsquo;anti-psychotics&rsquo;.</p><p>Respal is used to treat the following:</p><p>&bull; Schizophrenia, where you may see, hear or feel things that are not there, believe things that are not true or feel unusually suspicious, or confused.</p><p>&bull; Mania, where you may feel very excited, elated, agitated, enthusiastic or hyperactive. Mania occurs in an illness called &ldquo;bipolar disorder&rdquo;</p><p>&bull; Short-term treatment (up to 6 weeks) of long-term aggression in people with Alzheimer&rsquo;s dementia, who harm themselves or others. Alternative (non-drug) treatments should have been used previously.</p><p>&bull; Short-term treatment (up to 6 weeks) of long-term aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.</p><p>&bull; Respal can help alleviate the symptoms of your disease and stop your symptoms from coming back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>A. Do not take Respal:</p><p>&bull; If you are allergic to risperidone or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull; If you are not sure if the above applies to you, talk to your doctor or pharmacist before using Respal.</p><p>B. Take special care with Respal:</p><p>Talk to your doctor or pharmacist before taking Respal if:</p><p>&bull; You have a heart problem. Examples include an irregular heart rhythm or if you are prone to low blood pressure or if you are using medicines for your blood pressure. Respal may cause low blood pressure. Your dose may need to be adjusted</p><p>&bull; You know of any factors which would favour you having a stroke, such as high blood pressure, cardiovascular disorder or blood vessel problems in the brain</p><p>&bull; You have ever experienced involuntary movements of the tongue, mouth and face</p><p>&bull; You have ever had a condition whose symptoms include high temperature, muscle stiffness, sweating or a lowered level of consciousness (also known as Neuroleptic Malignant Syndrome)</p><p>&bull; You have Parkinson&rsquo;s disease or dementia</p><p>&bull; You know that you have had low levels of white blood cells in the past (which may or may not have been caused by other medicines)</p><p>&bull; You are diabetic</p><p>&bull; You have epilepsy</p><p>&bull; You are a man and you have ever had a prolonged or painful erection</p><p>&bull; You have problems controlling your body temperature or overheating</p><p>&bull; You have kidney problems</p><p>&bull; You have liver problems</p><p>&bull; You have an abnormally high level of the hormone prolactin in your blood or if you have a possible prolactin-dependent tumour.</p><p>&bull; You or someone else in your family has a history of blood clots, as antipsychotics have been associated with formation of blood clots.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Respal.</p><p>As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking Respal, your doctor may check your white blood cell counts.</p><p>Respal may cause you to gain weight. Significant weight gain may adversely affect your health. Your doctor should regularly measure your body weight.</p><p>As diabetes mellitus or worsening of pre-existing diabetes mellitus has been seen with patients taking Respal, your doctor should check for signs of high blood sugar. In patients with pre-existing diabetes mellitus blood glucose should be monitored regularly.</p><p>Respal commonly raises levels of a hormone called &quot;prolactin&quot;. This may cause side effects such as menstrual disorders or fertility problems in women, breast swelling in men (see possible side effects). If such side effects occur, evaluation of the prolactin level in the blood is recommended.</p><p>During an operation on the eye for cloudiness of the lens (cataract), the pupil (the black circle in the middle of your eye) may not increase in size as needed. Also, the iris (the coloured part of the eye) may become floppy during surgery and that may lead to eye damage. If you are planning to have an operation on your eye, make sure you tell your eye doctor that you are taking this medicine.</p><p>Elderly people with dementia:</p><p>In elderly patients with dementia, there is an increased risk of stroke. You should not take risperidone if you have dementia caused by stroke.</p><p>During treatment with risperidone you should frequently see your doctor.</p><p>Medical treatment should be sought straight away if you or your care-giver notice a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke.</p><p>Children and adolescents:</p><p>Before treatment is started for conduct disorder, other causes of aggressive behaviour should have been ruled out.</p><p>If during treatment with risperidone tiredness occurs, a change in the time of administration might improve attention difficulties.</p><p>Before treatment is started your, or your child&rsquo;s body weight may be measured and it may be regularly monitored during treatment.</p><p>A small and inconclusive study has reported an increase in height in children who took risperidone, but whether this is an effect of the drug or due to some other reason is not known.</p><p>C. Taking other medicines:</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>It is especially important to talk to your doctor or pharmacist if you are taking any of the following:</p><p>&bull; Medicines that work on your brain such as to help you calm down (benzodiazepines) or some medicines for pain (opiates), medicines for allergy (some antihistamines), as risperidone may increase the sedative effect of all of these</p><p>&bull; Medicines that may change the electrical activity of your heart, such as medicines for malaria, heart rhythm problems, allergies (anti-histamines), some antidepressants or other medicines for mental problems</p><p>&bull; Medicines that cause a slow heart beat</p><p>&bull; Medicines that cause low blood potassium (such as certain diuretics)</p><p>&bull; Medicines to treat raised blood pressure. Respal can lower blood pressure</p><p>&bull; Medicines for Parkinson&#39;s disease (such as levodopa)</p><p>&bull; Water tablets (diuretics) used for heart problems or swelling of parts of your body due to a build up of too much fluid (such as furosemide or chlorothiazide). Respal taken by itself or with furosemide,may have an increased risk of stroke or death in elderly people with dementia.</p><p>The following medicines may reduce the effect of risperidone:</p><p>&bull; Rifampicin (a medicine for treating some infections)</p><p>&bull; Carbamazepine, phenytoin (medicines for epilepsy)</p><p>&bull; Phenobarbital</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p>The following medicines may increase the effect of risperidone:</p><p>&bull; Quinidine (used for certain types of heart disease)</p><p>&bull; Antidepressants such as paroxetine, fluoxetine, tricyclic antidepressants</p><p>&bull; Medicines known as beta blockers (used to treat high blood pressure)</p><p>&bull; Phenothiazines (such as medicines used to treat psychosis or to calm down)</p><p>&bull; Cimetidine, ranitidine (blockers of the acidity of stomach)</p><p>&bull; Itraconazole and ketoconazole (medicines for treating fungal infections)</p><p>&bull; Certain medicines used in the treatment of HIV/AIDS, such as ritonavir</p><p>&bull; Verapamil, a medicine used to treat high blood pressure and/or abnormal heart rhythm.</p><p>&bull; Sertraline and fluvoxamine, medicines used to treat depression and other psychiatric disorders.</p><p>If you start or stop taking such medicines you may need a different dose of risperidone.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Respal.</p><p>D. Taking Respal with food, drink and alcohol:</p><p>You can take this medicine with or without food. You should avoid drinking alcohol when taking Respal.</p><p>E. Pregnancy, breast-feeding and fertility:</p><p>&bull; If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide if you can take it</p><p>&bull; The following symptoms may occur in newborn babies, of mothers that have used Respal in the last trimester (last three months of their pregnancy): shaking, muscle stiffness, and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>&bull; Respal can raise your levels of a hormone called &quot;prolactin&quot; that may impact fertility (see Possible side effects).</p><p>F. Driving and using machines:</p><p>Dizziness, tiredness, and vision problems may occur during treatment with Respal. Do not drive or use any tools or machines without talking to your doctor first.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is as follows:</p><p>For the treatment of schizophrenia</p><p>Adults</p><p>&bull; The usual starting dose is 2 mg per day, this may be increased to 4 mg per day on the second day</p><p>&bull; Your dose may then be adjusted by your doctor depending on how you respond to the treatment</p><p>&bull; Most people feel better with daily doses of 4 to 6 mg</p><p>&bull; This total daily dose can be divided into either one or two doses a day. Your doctor will tell you which is the best for you.</p><p>Elderly people</p><p>&bull; Your starting dose will normally be 0.5 mg twice a day</p><p>&bull; Your dose may then be gradually increased by your doctor to 1 mg to 2 mg twice a day</p><p>&bull; Your doctor will tell you which is the best for you.</p><p>For the treatment of mania:</p><p>Adults:</p><p>&bull; Your starting dose will usually be 2 mg once a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>&bull; Most people feel better with doses of 1 to 6 mg once a day.</p><p>Elderly people:</p><p>&bull; Your starting dose will usually be 0.5 mg twice a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor to 1 mg to 2 mg twice a day depending on how much you respond to the treatment.</p><p>For the treatment of long-standing aggression in people with Alzheimer&rsquo;s dementia:</p><p>Adults (including elderly people):</p><p>&bull; Your starting dose will normally be 0.25 mg twice a day</p><p>&bull; Your dose may then be gradually adjusted by your doctor depending on how you respond to the treatment</p><p>&bull; Most people feel better with 0.5 mg twice a day. Some patients may need 1 mg twice a day</p><p>&bull; Treatment duration in patients with Alzheimer&rsquo;s dementia should be not more than 6 weeks.</p><p>Use in children and adolescents:</p><p>&bull; Children and adolescents under 18 years old should not be treated with Respal for schizophrenia or mania.</p><p>For the treatment of conduct disorder</p><p>The dose will depend on your child&rsquo;s weight:</p><p>For children who weigh less than 50 kg</p><p>&bull; The starting dose will normally be 0.25 mg once a day</p><p>&bull; The dose may be increased every other day in steps of 0.25 mg per day.</p><p>&bull; The usual maintenance dose is 0.25 mg to 0.75 mg once a day.</p><p>For children who weigh 50 kg or more:</p><p>&bull; The starting dose will normally be 0.5 mg once a day</p><p>&bull; The dose may be increased every other day in steps of 0.5 mg per day.</p><p>&bull; The usual maintenance dose is 0.5 mg to 1.5 mg once a day.</p><p>Treatment duration in patients with conduct disorder should be not more than 6 weeks.</p><p>Children under 5 years old should not be treated with Respal for conduct disorder.</p><p>People with kidney or liver problems:</p><p>Regardless of the disease to be treated, all starting doses and following doses of risperidone should be halved. Dose increases should be slower in these patients.</p><p>Risperidone should be used with caution in this patient group.</p><p>Method of administration:</p><p>For oral use.</p><p>A. If you take more Respal than you should:</p><p>&bull; See a doctor right away. Take the medicine pack with you</p><p>&bull; In case of overdose you may feel sleepy or tired, or have abnormal body movements, problems standing and walking, feel dizzy due to low blood pressure, or have abnormal heartbeats or fits.</p><p>B. If you forget take Respal:</p><p>If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose and continue as usual. If you miss two or more doses, contact your doctor</p><p>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p>C. If you stop taking Respal:</p><p>You should not stop taking this medicine unless told to do so by your doctor. Your symptoms may return. If your doctor decides to stop this medicine, your dose may be decreased gradually over a few days.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you:</p><p>&bull; Experience blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any of these symptoms seek medical advice immediately</p><p>&bull; Have dementia and experience a sudden change in your mental state or sudden weakness or numbness of your face, arms or legs, especially on one side, or slurred speech, even for a short period of time. These may be signs of a stroke</p><p>&bull; Experience fever, muscle stiffness, sweating or a lowered level of consciousness (a disorder called &ldquo;Neuroleptic Malignant Syndrome&rdquo;). Immediate medical treatment may be needed</p><p>&bull; Are a man and experience prolonged or painful erection. This is called priapism. Immediate medical treatment may be needed</p><p>&bull; Experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of risperidone may be needed</p><p>&bull; Experience severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash or drop in blood pressure.</p><p>The following side effects may happen:</p><p>Very Common (may affect more than 1 in 10 people):</p><p>&bull; Difficulty falling or staying asleep</p><p>&bull; Parkinsonism: This condition may include: slow or impaired movement, sensation of stiffness or tightness of the muscles (making your movements jerky), and sometimes even a sensation of movement &quot;freezing up&quot; and then restarting. Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.</p><p>&bull; Feeling sleepy, or less alert</p><p>&bull; Headache.</p><p>Common (may affect up to 1 in 10 people):</p><p>&bull; Pneumonia, Infection of the chest (bronchitis), Common cold symptoms, Sinus infection, Urinary tract infection, Ear infection, Feeling like you have the flu</p><p>&bull; Raised levels of a hormone called &quot;prolactin&quot; found in a blood test (which may or may not cause symptoms). Symptoms of high prolactin occur uncommonly and may include in men breast swelling, difficulty in getting or maintaining erections, decreased sexual desire or other sexual dysfunction. In women they may include&nbsp; breast discomfort, leakage of milk from the breasts, missed menstrual periods, or other problems with your cycle or fertility problems.</p><p>&bull; Weight gain, Increased appetite, Decreased appetite</p><p>&bull; Sleep disorder, Irritability, Depression, Anxiety, Restlessness</p><p>&bull; Dystonia: This is a condition involving slow or sustained involuntary contraction of muscles. While it can involve any part of the body (and may result in abnormal posture), dystonia often involves muscles of the face, including abnormal movements of the eyes, mouth, tongue or jaw.</p><p>&bull; Dizziness</p><p>&bull; Dyskinesia: This is a condition involving involuntary muscle movements, and can include repetitive, spastic or writhing movements, or twitching.</p><p>&bull; Tremor (shaking)</p><p>&bull; Blurry vision, Eye infection or &quot;pink eye&quot;</p><p>&bull; Rapid heart rate, High blood pressure, Shortness of breath</p><p>&bull; Sore throat, Cough, Nosebleeds, Stuffy nose</p><p>&bull; Abdominal pain, Abdominal discomfort, Vomiting, Nausea, Constipation, Diarrhea, Indigestion, Dry mouth, Toothache</p><p>&bull; Rash, Skin redness</p><p>&bull; Muscle spasms, Bone or muscle ache, Back pain, Joint pain</p><p>&bull; Incontinence (lack of control) of urine</p><p>&bull; Swelling of the body, arms or legs, Fever, Chest pain, Weakness, Fatigue (tiredness), Pain</p><p>&bull; Fall.</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>&bull; Infection of the breathing passages, Bladder infection, &lsquo;Eye infection, Tonsillitis, Fungal infection of the nails, Infection of the skin, An infection confined to a single area of skin or part of the body, Viral infection, Skin inflammation caused by mites</p><p>&bull; Decrease in the type of white blood cells that help to protect you against infection, White blood cell count decreased, Decrease in platelets (blood cells that help you stop bleeding), Anemia, Decrease in red blood cells, Increase in eosinophils (a type of white blood cell) in your blood</p><p>&bull; Allergic reaction</p><p>&bull; Diabetes or worsening of diabetes, High blood sugar, Excessive drinking of water</p><p>&bull; Weight loss, Loss of appetite resulting in malnutrition and low body weight</p><p>&bull; Increased cholesterol in your blood</p><p>&bull; Elated mood (mania), Confusion, Decreased sexual drive, Nervousness, Nightmares</p><p>&bull; Tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body). Tell your doctor immediately if you experience involuntary rhythmic movements of the tongue, mouth and face. Withdrawal of Respal may be needed</p><p>&bull; Sudden loss of blood supply to brain (stroke or &quot;mini&quot; stroke)</p><p>&bull; Unresponsive to stimuli, Loss of consciousness, Low level of consciousness</p><p>&bull; Convulsion (fits), Fainting</p><p>&bull; A restless urge to move parts of your body, Balance disorder, Abnormal coordination, Dizziness upon standing, Disturbance in attention, Problems with speech, Loss or abnormal sense of taste, Reduced sensation of skin to pain and touch, A sensation of tingling, pricking, or numbness skin</p><p>&bull; Oversensitivity of the eyes to light, Dry eye, Increased tears, Redness of the eyes</p><p>&bull; Sensation of spinning (vertigo), Ringing in the ears, Ear pain</p><p>&bull; Atrial fibrillation (an abnormal heart rhythm), An interruption in conduction between the upper and lower parts of the heart, Abnormal electrical conduction of the heart, Prolongation of the QT interval from your heart, Slow heart rate, Abnormal electrical tracing of the heart (electrocardiogram or ECG), A fluttering or pounding feeling in your chest (palpitations)</p><p>&bull; Low blood pressure, Low blood pressure upon standing (consequently, some people taking taking Respal may feel faint, dizzy, or may pass out when they stand up or sit up suddenly, Flushing</p><p>&bull; Pneumonia caused by inhaling food, Lung congestion, Congestion of breathing passages, Crackly lung sounds, Wheezing, Voice disorder, Breathing passage disorder</p><p>&bull; Stomach or intestinal infection, Stool incontinence, Very hard stool, Difficulty swallowing, Excessive passing of gas or wind</p><p>&bull; Hives (or &quot;nettle rash&quot;), Itching, Hair loss, Thickening of skin, Eczema, Dry skin, Skin discoloration, Acne, Flaky, itchy scalp or skin, Skin disorder, Skin lesion</p><p>&bull; An increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown</p><p>&bull; Abnormal posture, Joint stiffness, Joint swelling, Muscle weakness, Neck pain</p><p>&bull; Frequent passing of urine, Inability to pass urine, Pain when passing urine</p><p>&bull; Erectile dysfunction, Ejaculation disorder</p><p>&bull; Loss of menstrual periods, Missed menstrual periods or other problems with your cycle (females)</p><p>&bull; Development of breasts in men, Leakage of milk from the breasts, Sexual dysfunction, Breast pain, Breast discomfort, Vaginal discharge</p><p>&bull; Swelling of the face, mouth, eyes, or lips</p><p>&bull; Chills, An increase in body temperature</p><p>&bull; A change in the way you walk</p><p>&bull; Feeling thirsty, Feeling unwell, Chest discomfort, Feeling &quot;out of sorts&quot;, Discomfort</p><p>&bull; Increased liver transaminases in your blood, Increased GGT (a liver enzyme called gamma-glutamyltransferase) in your blood, Increased liver enzymes in your blood</p><p>&bull; Procedural pain.</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>&bull; Infection</p><p>&bull; Inappropriate secretion of a hormone that controls urine volume</p><p>&bull; Sugar in the urine, Low blood sugar, High blood triglycerides (a fat)</p><p>&bull; Lack of emotion, Inability to reach orgasm</p><p>&bull; Neuroleptic malignant syndrome (confusion, reduced or loss of consciousness, high fever, and severe muscle stiffness)</p><p>&bull; Blood vessel problems in the brain</p><p>&bull; Coma due to uncontrolled diabetes</p><p>&bull; Shaking of the head</p><p>&bull; Glaucoma (increased pressure within the eyeball), Problems with movement of your eyes, Eye rolling, Eyelid margin crusting</p><p>&bull; Eye problems during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) can happen if you take or have taken Respal. If you need to have cataract surgery, be sure to tell your eye doctor if you take or have taken this medicine.</p><p>&bull; Dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood</p><p>&bull; Severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure</p><p>&bull; Dangerously excessive intake of water</p><p>&bull; Irregular heart beat</p><p>&bull; Blood clot in the legs, Blood clot in the lungs</p><p>&bull; Trouble breathing during sleep (sleep apnea), Fast, shallow breathing</p><p>&bull; Inflammation of the pancreas, A blockage in the bowels</p><p>&bull; Swollen tongue, Chapped lips, Rash on skin related to drug</p><p>&bull; Dandruff</p><p>&bull; Breakdown of muscle fibers and pain in muscles (rhabdomyolysis)</p><p>&bull; A delay in menstrual periods, Enlargement of the glands in your breasts, Breast enlargement, Discharge from the breasts</p><p>&bull; Increased insulin (a hormone that controls blood sugar levels) in your blood</p><p>&bull; Priapism (a prolonged penile erection that may require surgical treatment)</p><p>&bull; Hardening of the skin</p><p>&bull; Decreased body temperature, Coldness in arms and legs</p><p>&bull; Symptoms of drug withdrawal</p><p>&bull; Yellowing of the skin and the eyes (jaundice).</p><p>Very rare (may affect up to 1 in 10,000 people):</p><p>&bull; Life threatening complications of uncontrolled diabetes.</p><p>&bull; Serious allergic reaction with swelling that may involve the throat and lead to difficulty breathing</p><p>&bull; Lack of bowel muscle movement that causes blockage.</p><p>The following side effect has been seen with the use of another medicine called paliperidone that is very similar to risperidone, so these can also be expected with risperidone: Rapid heartbeat upon standing.</p><p>Additional side effects in children and adolescents</p><p>In general, side effects in children are expected to be similar to those in adults.</p><p>The following side effects were reported more often in children and adolescents (5 to 17 years) than in adults: feeling sleepy, or less alert, fatigue (tiredness), headache, increased appetite, vomiting, common cold symptoms, nasal congestion, abdominal pain, dizziness, cough, fever, tremor (shaking), diarrhoea, and incontinence (lack of control) of urine. If any of the side effects gets serious or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the reach and sight of children.</p><p>- Do not use Respal after the expiry date which is stated on the label and carton.</p><p>- This medicinal product does not require any special storage conditions.</p><p>- Do not use any Respal pack that is damaged or shows signs of tampering.</p><p>- Store at room temperature below 30oC.</p><p>- Do not use Respal Solution after the bottle has been opened for more than 3 months</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Respal Solution 1mg/1ml contains 1mg of Risperidone per 1ml oral Solution</p><p>The other ingredients are: Benzoic acid/ Sorbitol liquid 70%/ Saccharin Sodium/ Citric acid/ Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: Solution
Respal Solution pack size: 100 ml

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jordan Sweden Medical and Sterilization Company (JOSWE-medical)</p><p>P.O. Box 851831 Amman 11185 Jordan</p><p>E-mail: joswe@go.com.jo</p><p>www.joswe.com</p><p>Tel: +962 6 5859765, +962 6 5728327</p><p>Fax: +962 6 5814526, +962 6 5728326</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved on 3/2019; Revision number R0
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي ريسبال إلى مجموعة من الأدوية تدعى مضادات الذهان.</p><p>يستخدم ريسبال لعلاج الحالات التالية:</p><p>&bull; الفصام، حيث قد ترى، تسمع أو تشعر بأشياء غير موجودة، تصدق أمورا غير صحيحة أو تشعر على غير العادة بالشك، أو التشويش.</p><p>&bull; الهوس، حيث قد تشعربأنك متحمس جدا، مبتهج، هائج، حماسي أو نشط للغاية. يظهر الهوس في مرض يسمى &quot;اضطراب ثنائي القطب&quot;.</p><p>&bull; العلاج قصير الأمد (لمدة تصل إلى 6 أسابيع) لمرضى الزهايمر- الخرف طويل الأمد الذين يلحقون الأذى بأنفسهم أوبالآخرين. من المفترض أن يكون قد تم استخدام علاجات بديلة (غير دوائية) سابقاً.</p><p>&bull; العلاج قصير الأمد (لمدة تصل ل 6 أسابيع) في الأطفال المعاقين عقلياً (الذين تقل أعمارهم عن 5 سنوات) وفي المراهقين الذين يعانون من اضطراب السلوك.</p><p>&bull; يساعد ريسبال في التخفيف من أعراض المرض لديك وعدم عودتها مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>أ. لا تتناول ريسبال:</p><p>&bull; إذا كنت تعاني من حساسية ضد رسبريدون أو أي من المكونات الأخرى لهذا الدواء (المذكورة في بند رقم 6).</p><p>&bull; لم تكن متأكدا أن أي من المذكور أعلاه ينطبق عليك، تحدث مع الطبيب أو الصيدلاني قبل تناول ريسبال.</p><p>&nbsp;</p><p>ب. أخذ الحيطة والحذر مع ريسبال:</p><p>تحدث إلى الطبيب أو الصيدلاني قبل تناول ريسبال إذا:</p><p>&bull; إذا كنت تعاني من مشكلة في القلب. مثل عدم انتظام ضربات القلب أو إذا كنت معرضا لانخفاض ضغط الدم أو إذا كنت تستخدم أدوية لخفض ضغط الدم. قد يسبب ريسبال انخفاض في ضغط الدم. لذا قد تحتاج إلى تعديل الجرعة.</p><p>&bull; كنت على علم بأن لديك أي من العوامل التي قد تزيد من احتمالية إصابتك بالسكتة الدماغية، مثل ارتفاع ضغط الدم، اضطرابات الأوعية الدموية القلبية او مشاكل الأوعية الدموية في الدماغ.</p><p>&bull; كنت قد عانيت من حركات لا إرادية في اللسان، الفم أو الوجه.</p><p>&bull; كنت قد عانيت من حالة تتمثل أعراضها في ارتفاع درجة الحرارة، تصلب العضلات، التعرق أو تدني مستوى الوعي ( المعروف أيضا باسم متلازمة الذهان الخبيثة).</p><p>&bull; كنت تعاني من مرض باركنسون أو الخرف.</p><p>&bull; كنت على علم بأنك قد عانيت مسبقا من انخفاض مستويات خلايا الدم البيضاء (والتي قد تكون أو لا تكون ناجمة عن استخدام أدوية أخرى)</p><p>&bull; كنت مصاب بداء السكري</p><p>&bull; كنت مصاب بالصرع</p><p>&bull; كنت رجل وقد عانيت في أي وقت مضى من انتصاب مؤلم أو لفترة طويلة</p><p>&bull; كنت تعاني من مشاكل في السيطرة على درجة حرارة جسمك أو ارتفاع في درجة الحرارة</p><p>&bull; كنت تعاني من مشاكل في الكلى</p><p>&bull; كنت تعاني من مشاكل في الكبد</p><p>&bull; كنت تعاني من ارتفاع غير طبيعي في مستوى هرمون البرولاكتين في الدم أو إذا كان من المحتمل إصابتك بالورم المعتمد على البرولاكتين</p><p>&bull; كان لديك أنت أو لدى أي من أفراد عائلتك تاريخ إصابة بجلطات دموية، حيث أن مضادات الذهان مرتبطة بتشكل جلطات الدم.</p><p>إذا لم تكن متأكدا بأن أي من الأمور المذكورة أعلاه ينطبق عليك، تحدث مع الطبيب أو الصيدلاني قبل تناول ريسبال</p><p>لقد تم تسجيل حالات نادرة جدا وخطيرة في المرضى الذين يتناولون ريسبال وهي انخفاض في نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم، لذا فإن طبيبك قد يتحقق من عدد خلايا الدم البيضاء الخاصة بك.</p><p>قد يسبب ريسبال زيادة في الوزن. الزيادة الملحوظة في الوزن قد تؤثر سلبا على صحتك. على طبيبك قياس وزنك بانتظام</p><p>تم تسجيل حالات إصابة بداء السكري أو تفاقم في داء السكري لدى المرضى الذين يتناولون ريسبال لذا على الطبيب التحقق من علامات ارتفاع السكر في الدم. على المرضى المصابين بداء السكري فحص غلوكوز الدم بانتظام.</p><p>يعمل ريسبال عادة على رفع مستويات هرمون يدعى &quot;البرولاكتين&quot;. وقد يسبب هذا آثار جانبية مثل اضطراب الدورة الشهرية أو مشاكل في الخصوبة لدى النساء، تورم الثديين لدى الرجال (انظر الآثار الجانبية المحتملة). في حال حدوث مثل هذه الآثار الجانبية، يوصى بتقييم مستوى البرولاكتين في الدم.</p><p>خلال اجراء العمليات الجراحية لاعتمام العدسة، فان البؤبؤ (الدائرة السوداء في منتصف العين) قد لا يزداد حجمه كما هو مطلوب. أيضا، القزحية (الجزء الملون من العين) قد تصبح مرنة أثناء الجراحة مما قد يؤدي إلى حدوث ضرر في العين. فإذا كنت تخطط للخضوع لعملية جراحية في العين، يجب عليك إخبار طبيب العيون بأنك تتناول هذا الدواء.</p><p>كبار السن الذين يعانون من الخرف:</p><p>المرضى كبار السن المصابون بالخرف معرضون بشكل أكبر لخطر الإصابة بالسكتة الدماغية. عليك الامتناع عن تناول&nbsp; رسبريدون إذا كان الخرف الذي تعاني منه ناجم عن سكتة دماغية.</p><p>عليك مراجعة الطبيب بشكل مستمر خلال فترة العلاج باستخدام رسبريدون.</p><p>إذا لاحظت أنت أو لاحظ الشخص الذي يقوم على رعايتك حدوث تغيير مفاجئ في الحالة العقلية أو ضعف مفاجئ أو خدران في وجهك والذراعين أو الساقين، وخاصة إذا كانت في جانب واحد، أوتداخل الكلام، ولو لفترة قصيرة من الوقت. قد تكون هذه علامات للسكتة الدماغية.</p><p>الأطفال والمراهقين:</p><p>قبل البدء بعلاج اضطرابات السلوك، يجب استبعاد الأسباب الأخرى التي تسبب السلوك العدواني.</p><p>إذا كان هناك شعور بالتعب أثناء العلاج باستخدام رسبريدون، فإن تغيير وقت تناول الدواء قد يؤدي إلى تحسين صعوبات الانتباه.</p><p>قبل البدء بالعلاج يجب قياس وزنك أو وزن جسم طفلك وخلال العلاج يجب متابعته بشكل منتظم.</p><p>وقد سجلت دراسة صغيرة وغير حاسمة في الأطفال الذين تناولوا رسبريدون زيادة في الطول ، ولكن ما زال من غير المعروف ما إذا كان هذا تأثير الدواء أو إن كان يعود لأسباب أخرى.</p><p>ج. تناول أدوية أخرى:</p><p>يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p>فمن الضروري اخبار الطبيب أو الصيدلي خاصةً اذا كنت تتناول أي من الأدوية التالية:</p><p>&bull; الأدوية التي تعمل على الدماغ لمساعدتك على الهدوء (البنزوديازيبين) أو بعض الأدوية المخففة للألم (المواد الأفيونية)، وأدوية علاج الحساسية (مضادات الهيستامين)، وذلك لأن رسبريدون قد يزيد من التأثير المهدىء لهذه الأدوية.</p><p>&bull; الأدوية التي من الممكن أن تغير النشاط الكهربائي للقلب، مثل أدوية علاج الملاريا، وأدوية معالجة مشاكل ضربات القلب، وأدوية علاج الحساسية (مضادات الهيستامين)، وبعض مضادات الاكتئاب وغيرها من الأدوية المستخدمة لعلاج المشاكل العقلية.</p><p>&bull; الأدوية التي تسبب تباطؤ في ضربات القلب.</p><p>&bull; الأدوية التي تسبب انخفاض في مستوى البوتاسيوم في الدم (مثل بعض مدرات البول).</p><p>&bull; الأدوية المستخدمة لعلاج ارتفاع ضغط الدم. ريسبال قد يسبب انخفاض في ضغط الدم.</p><p>&bull; الأدوية المستخدمة لعلاج مرض الباركنسون (مثل ليفودوبا).</p><p>&bull; مدرات البول التي تستخدم لمعالجة مشاكل القلب أو تورم أجزاء من الجسم نتيجة لتراكم الكثير من السوائل (مثل فيوروسيميد أو الكلوروثيازايد). ريسبال لوحده أو مع فيوروسيميد ، قد يزيد من خطر الإصابة بالسكتة الدماغية أو الموت في كبار السن الذين يعانون من الخرف.</p><p>الأدوية التالية قد تقلل من تأثير رسبريدون</p><p>&bull; ريفامبيسين (دواء لعلاج بعض الالتهابات).</p><p>&bull; كاربامازيبين، فينيتوين (أدوية لعلاج الصرع).</p><p>&bull; فينوباربيتال.</p><p>قد تحتاج إلى تعديل جرعة رسبريدون إذا كنت بدأت أو توقفت عن تناول هذه الأدوية.</p><p>الأدوية التي تزيد من تأثير رسبريدون</p><p>&bull; كوينيدين (دواء يستخدم لعلاج أنواع معينة من أمراض القلب).</p><p>&bull; مضادات الاكتئاب مثل باروكسيتين، فلوكستين، ومضادات الاكتئاب ثلاثية الحلقات.</p><p>&bull; الأدوية المعروفة باسم حاصرات بيتا (أدوية تستخدم لعلاج ارتفاع ضغط الدم).</p><p>&bull; فينوثيازين (أدوية تستخدم لعلاج الذهان أو للتهدئة).</p><p>&bull; سيميتيدين، رانيتيدين (أدوية تستخدم لعلاج حموضة المعدة).</p><p>&bull; إتراكونازول وكيتوكونازول (أدوية تستخدم لعلاج الإلتهابات الفطرية).</p><p>&bull; بعض الأدوية المستخدمة في علاج فيروس نقص المناعة البشرية/ الإيدز، مثل ريتونافير.</p><p>&bull;&nbsp; فيراباميل، وهو دواء يستخدم لعلاج ارتفاع ضغط الدم و/ أو ضربات القلب غير الطبيعية.</p><p>&bull; سيرترالين وفلوفوكسامين، الأدوية المستخدمة لعلاج الاكتئاب والإضطرابات النفسية الأخرى.</p><p>قد تحتاج إلى تعديل الجرعة من رسبريدون إذا كنت بدأت أو توقفت عن تناول هذه الأدوية.</p><p>إذا لم تكن متأكدا بأن ما ذكر أعلاه ينطبق عليك أم لا، قم باستشارة الطبيب أو الصيدلي قبل تناول ريسبال.</p><p>د. تناول ريسبال مع الطعام، الشراب والكحول:</p><p>يمكنك تناول ريسبال مع أو بدون الطعام. يجب تجنب شرب الكحول عند تناول ريسبال.</p><p>ه. الحمل والإرضاع:</p><p>إذا كنت حامل أو مرضعة أو&nbsp; تعتقدين أنك حامل أو تخططين للإنجاب قومي باستشارة الطبيب قبل تناول هذا الدواء. والطبيب هو الذي سوف يقرر إذا كنت تستطيعين تناول هذا الدواء أم لا.</p><p>قد تظهر الأعراض التالية على الأطفال حديثي الولادة للأمهات اللاتي تناولن ريسبال في الثلث الأخير من الحمل (الأشهر الثلاثة الأخيرة من الحمل): الاهتزاز، وتصلب العضلات، و/أو الضعف، والنعاس، والإثارة، ومشاكل في التنفس، وصعوبة في الرضاعة. يجب عليك التواصل مع الطبيب إذا كان طفلك يعاني من أحد هذه الأعراض.</p><p>&bull; قد يؤدي استخدام ريسبال إلى ارتفاع مستويات هرمون يدعى &quot;البرولاكتين&quot; الذي يؤثر على الخصوبة (انظر إلى قسم الآثار الجانبية المحتملة).</p><p>و. القيادة واستخدام الآلات:</p><p>أثناء العلاج باستخدام ريسبال قد تحدث دوخة، وتعب، ومشاكل في الرؤية لذا لا تقد أو تستخدم أي أدوات أو آلات دون التحدث مع طبيبك أولاً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائماً قم بتناول هذا الدواء كما أخبرك الطبيب أو الصيدلاني. قم باستشارة الطبيب أو الصيدلاني، إذا لم تكن متأكداً .</p><p>الجرعة الموصى بها هي على النحو التالي:</p><p>علاج الفصام</p><p>البالغين</p><p>&bull; جرعة البدء المعتادة هي 2 ملغم يومياً، يمكن زيادة هذه الجرعة في اليوم الثاني إلى 4 ملغم يومياً.</p><p>&bull; يمكن بعد ذلك تعديل الجرعة الخاصة بك من قبل الطبيب حسب استجابتك للعلاج.</p><p>&bull; معظم الناس تشعر بالتحسن عند تناول جرعة يومية تتراوح من 4 إلى 6 ملغم.</p><p>&bull; يمكن تقسيم هذه الجرعة اليومية إلى جرعة واحدة أو إلى جرعتين في اليوم. طبيبك سوف يحدد ما هو الأفضل بالنسبة لك.</p><p>كبار السن</p><p>&bull; جرعة البدء المعتادة هي 0.5 ملغم مرتين في اليوم.</p><p>&bull; يمكن بعد ذلك زيادة الجرعه الخاصة بك تدريجياً من قبل الطبيب من 1 ملغم إلى 2 ملغم مرتين في اليوم.</p><p>&bull; طبيبك سوف يحدد ما هو الأفضل بالنسبة لك.</p><p>علاج الهوس</p><p>البالغين</p><p>&bull; جرعة البدء المعتادة هي 2 ملغم مرة واحدة يومياً.</p><p>&bull; يمكن بعد ذلك تعديل الجرعة الخاصة بك تدريجياً من قبل الطبيب حسب استجابتك للعلاج.</p><p>&bull; معظم الناس تشعر بالتحسن عند تناول جرعة يومية تتراوح من 1 إلى 6 ملغم.</p><p>كبار السن</p><p>&bull; جرعة البدء المعتادة هي 0.5 ملغم مرتين في اليوم.</p><p>&bull; بعد ذلك زيادة الجرعه الخاصة بك تدريجياً من قبل الطبيب من 1 ملغم إلى 2 ملغم مرتين في اليوم حسب استجابتك للعلاج.</p><p>علاج مرضى الزهايمر- الخرف المصابين بالسلوك العدواني طويل الأمد</p><p>البالغين (بما في ذلك كبار السن)</p><p>&bull; جرعة البدء المعتادة هي 0.25 ملغم مرتين في اليوم.</p><p>&bull;&nbsp; يمكن بعد ذلك تعديل الجرعة الخاصة بك تدريجياً من قبل الطبيب حسب استجابتك للعلاج.</p><p>&bull; معظم الناس تشعر بالتحسن عند تناول جرعة يومية 0.5 ملغم مرتين في اليوم. بعض المرضى قد يحتاجون لجرعة 1 ملغم مرتين في اليوم.</p><p>&bull; يجب أن لا تتجاوز مدة العلاج في المرضى الذين يعانون من الزهايمر- الخرف أكثر من 6 أسابيع.</p><p>الإستخدام من قبل الأطفال والمراهقين</p><p>&bull; لا يجب معالجة الأطفال والمراهقين دون سن 18 عام من الفصام أو الهوس باستخدام ريسبال.</p><p>علاج اضطرابات السلوك</p><p>سوف تعتمد الجرعة على وزن طفلك:</p><p>للأطفال الذين تقل أوزانهم عن 50 كغم</p><p>&bull; جرعة البدء المعتادة هي 0.25 ملغم مرة واحدة يومياً.</p><p>&bull; يمكن زيادة الجرعة تدريجياً يوم بعد يوم&nbsp; بمقدار 0.25 ملغم/ اليوم.</p><p>&bull; الجرعة الإستمرارية المعتادة هي تتراوح&nbsp; من 0.25 ملغم إلى 0.75 ملغم مرة واحدة يومياً.</p><p>للأطفال الذين أوزانهم 50 كغم أو أكثر</p><p>&bull; جرعة البدء المعتادة هي 0.5 ملغم مرة واحدة يومياً.</p><p>&bull; يمكن زيادة الجرعة تدريجياً يوم بعد يوم بمقدار 0.5 ملغم/ اليوم.</p><p>&bull; الجرعة الإستمرارية المعتادة هي تتراوح&nbsp; من 0.5 ملغم إلى 1.5 ملغم مرة واحدة يومياً.</p><p>وينبغي أن لا تتجاوز مدة العلاج في المرضى الذين يعانون من اضطرابات السلوك أكثر من 6 أسابيع.</p><p>الأطفال الذين تقل أعمارهم عن&nbsp; 5 سنوات لا يجب معالجتهم من اضطراب السلوك باستخدام ريسبال.</p><p>الأشخاص الذين يعانون من مشاكل في الكلى أو الكبد:</p><p>يجب على هؤلاء المرضى أن يتناولوا نصف الجرعة المعتادة للبدء أو الاستمرار في العلاج بغض النظر عن المرض المراد علاجه. كما ويكون تعديل الجرعة بشكل أبطأ في هؤلاء المرضى.</p><p>يجب أن يستخدم رسبريدون بحذر في هذه المجموعة من المرضى.</p><p>طريقة الإستخدام</p><p>للإستخدام عن طريق الفم</p><p>أ. إذا تناولت جرعة من ريسبال أكثر من اللازم:</p><p>&bull; راجع الطبيب على الفور. مصطحباً معك علبة الدواء.</p><p>&bull; في حالة فرط الجرعة قد تشعر بالنعاس أو التعب، أو قد يكون لديك حركات غير طبيعية، ومشاكل الوقوف والمشي، والشعور بالدوار بسبب انخفاض ضغط الدم، أو دقات قلب غير طبيعية أو نوبات.</p><p>ب. إذا نسيت تناول ريسبال:</p><p>إذا نسيت تناول الجرعة قم بتناولها عند تذكرها. على أية حال، إذا اقترب موعد الجرعة التالية، قم بتخط الجرعة المنسية ولا تتناولها واستمر بتناول الدواء كالمعتاد. في حال نسيت تناول جرعتين أو أكثر قم بالتواصل مع الطبيب.</p><p>لا تتناول جرعة مضاعفة (جرعتين في نفس الوقت) للتعويض عن الجرعة المنسية.</p><p>ج. إذا توقفت عن تناول ريسبال:</p><p>يجب أن لا تتوقف عن تناول هذا الدواء ما لم يطلب منك الطبيب ذلك. وذلك لأنه من الممكن أن تعود أعراض المرض من جديد. إذا قرر الطبيب وقف هذا الدواء، قد يتم خفض الجرعة تدريجياً على مدى بضعة أيام.</p><p>إذا كان لديك أي أسئلة اضافية عن استعمال هذا الدواء، قم باستشارة الطبيب أو الصيدلاني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثار جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p>أخبر طبيبك فورا إذا كنت:</p><p>&bull; تعاني من جلطات في الأوردة وخاصة في الساقين (وتشمل الأعراض تورم، وألم، واحمرار الساق)،والتي من الممكن أن تنتقل عبر الأوعية الدمويةإلى الرئتين مسببة ألم في الصدر وصعوبة في التنفس. إذا لاحظت أيا من هذه الأعراض اطلب المشورة الطبية فورا.</p><p>&bull; تعاني من الخرف ولاحظت تغيير مفاجئ في الحالة العقلية أو ضعف مفاجئ أو خدر في وجهك والذراعين أو الساقين وخاصة إذا كانت في جانب واحد، أو كلام متداخل، ولو لفترة قصيرة من الوقت. لأنه قد تكون هذه علامات السكتة الدماغية.</p><p>&bull; تعاني من الحمى، تصلب العضلات، والتعرق أو مستوى منخفض من الوعي (اضطراب يسمى &quot;متلازمة مضادات الذهان الخبيثة&quot;)، قد تكون هناك حاجة إلى العلاج الطبي الفوري.</p><p>&bull; رجل و تعرضت لانتصاب طويل ومؤلم (قساح)، قد تكون هناك حاجة إلى العلاج الطبي الفوري.</p><p>&bull; تعاني من حركات ايقاعية لا إرادية في اللسان، الفم والوجه،&nbsp; قد تكون هناك حاجة الى التوقف عن تناول رسبريدون.</p><p>&bull; تعاني من رد فعل تحسسي يتميز بالحمى وتورم الفم والوجه والشفاه أو اللسان، وضيق في التنفس، والحكة، الطفح الجلدي أو انخفاض في ضغط الدم.</p><p>قد تحدث الآثار الجانبية التالية:</p><p>شائعة جداً (من الممكن أن تصيب أكثر من شخص لكل 10 أشخاص):</p><p>&bull; صعوبة في النوم أو البقاء نائماً.</p><p>&bull; باركنسون/الرعاش: ويمكن أن تشمل هذه الحالة: ضعف أو بطء الحركة، والإحساس بتصلب أو ضيق في العضلات (تشنج في الحركة)، وأحيانا الإحساس بتجمد الحركة ، ومن ثم تعود القدرة على الحركة من جديد. وتشمل علامات الرعاش الأخرى بطء وجر القدمين عند المشي ، هزة عند الراحة، وزيادة اللعاب و/أو سيلانه، وفقدان التعبير على الوجه.</p><p>&bull; الشعور بالنعاس وقلة التيقظ.</p><p>&bull; الصداع.</p><p>شائعة (من الممكن أن تصيب لغاية شخص لكل 10 أشخاص):</p><p>&bull; الإلتهاب الرئوي وإلتهاب الصدر (التهاب الشعب الهوائية)، وأعراض نزلات البرد الشائعة، إلتهاب الجيوب الأنفية، إلتهاب المسالك البولية، عدوى الأذن، والشعور وكأنك مصاب بالانفلونزا.</p><p>&bull; قد يتسبب ريسبال بارتفاع مستوى هرمون يدعى &quot;البرولاكتين&quot; في فحص الدم (والذي بدوره من الممكن أن يسبب أو لا يسبب أعراض). تحدث أعراض ارتفاع البرولاكتين بشكل غير شائع ومن الممكن أن تتضمن في الرجال تورم الثدي، وصعوبة في حدوث أو الحفاظ على الانتصاب، انخفاض الرغبة الجنسية أو غيرها من أشكال العجز الجنسي. أما في النساء فإنها قد تشمل عدم الراحة في الثدي، وتسرب الحليب من الثديين، وغياب الدورة الشهرية، أو مشاكل أخرى في الدورة الشهرية أو مشاكل في الخصوبة.</p><p>&bull; زيادة الوزن، زيادة الشهية، وانخفاض الشهية.</p><p>&bull; اضطراب النوم، والتهيج، والاكتئاب، والقلق، وعدم الراحة.</p><p>&bull; خلل التوتر العضلي: هذه حالة تتضمن انقباض لا إرادي للعضلات بشكل بطيء أو مستمر. مع أنه قد تكون هذه الحالة في أي جزء من الجسم (ويمكن أن تؤدي الى وقفة غير طبيعية)، إلّا أن خلل التوتر غالباً ما يحدث في عضلات الوجه، بما في ذلك حركات غير طبيعية للعينين، الفم، اللسان أو الفك.</p><p>&bull; دوخة.</p><p>&bull; خلل الحركة: هي حالة تتضمن حركات لاإرادية للعضلات، ويمكن أن تشمل الحركات المتكررة، المتشنجة أو المتلوية، أو الوخز.</p><p>&bull; الرعشة (الهزة).</p><p>&bull; ضبابية الرؤية، وعدوى العين أو &quot;العين الوردية&quot;.</p><p>&bull; سرعة دقات القلب، ارتفاع ضغط الدم، ضيق في التنفس.</p><p>&bull; إلتهاب الحلق، السعال، نزيف الأنف، انسداد الأنف.</p><p>&bull; ألم وعدم راحة في البطن ، التقيؤ، الغثيان، الإمساك، الإسهال، عسر الهضم، جفاف الفم، وجع الأسنان.</p><p>&bull; الطفح الجلدي، احمرار الجلد.</p><p>&bull; تشنجات العضلات، آلام العظام أو العضلات ، آلام الظهر، آلام المفاصل.</p><p>&bull; سلس البول (عدم التحكم).</p><p>&bull; تورم الجسم والذراعين أو الساقين، حمى، ألم في الصدر، الضعف، التعب، الألم.</p><p>&bull; السقوط.</p><p>غير شائعة (من الممكن أن تصيب لغاية شخص لكل 100 شخص):</p><p>&bull; إلتهاب القصبات، إلتهاب المثانة، إلتهاب العين، إلتهاب اللوزتين، العدوى الفطرية للأظافر، عدوى الجلد، وعدوى محصورة في منطقة واحدة من الجلد أو جزء من الجسم، والعدوى الفيروسية، وإلتهاب الجلد الناجم عن العث.</p><p>&bull; انخفاض في أحد أنواع خلايا الدم البيضاء التي تساعد في الحماية ضد العدوى، وانخفاض عدد خلايا الدم البيضاء، انخفاض في الصفائح الدموية (خلايا الدم التي تساعد على إيقاف النزيف)، فقر الدم، وانخفاض في خلايا الدم الحمراء، وزيادة في الحمضات (وهو نوع من خلايا الدم البيضاء) في الدم.</p><p>&bull; رد فعل تحسسي.</p><p>&bull; الإصابة بداء السكري أو تفاقم داء السكري، ارتفاع الجلوكوز الدم، الشرب المفرط للماء.</p><p>&bull; فقدان الوزن، فقدان الشهية مما يؤدي إلى سوء التغذية وانخفاض وزن الجسم.</p><p>&bull; زيادة نسبة الكوليسترول في الدم.</p><p>&bull; مزاج مبتهج (الهوس)، والارتباك، وانخفاض الدافع الجنسي، والعصبية، والكوابيس.</p><p>&bull; خلل الحركة المتأخر (الوخز أو رجيج الحركات التي لا يمكنك التحكم فيها في وجهك، واللسان، أو أجزاء أخرى من الجسم). أخبر طبيبك فورا إذا حدث معك حركات إيقاعية غير إرادية في اللسان، الفم والوجه. قد تكون هناك حاجة&nbsp; إلى التوقف عن تناول ريسبال.</p><p>&bull; التوقف المفاجىء لتدفق الدم إلى الدماغ (سكتة دماغية أو سكتة دماغية مصغرة).</p><p>&bull; عدم الإستجابة للمحفزات، فقدان الوعي، ومستوى منخفض من الوعي.</p><p>&bull; التشنج (نوبات)، الإغماء.</p><p>&bull; رغبة في تحريك أجزاء من الجسم، واضطراب التوازن، الدوخة عند الوقوف، واضطراب في الانتباه، ومشاكل في الكلام، وفقدان أو شعور غير طبيعي للطعم، وانخفاض إحساس الجلد بالألم واللمس، والإحساس بالوخز، التنميل، أو خدران الجلد.</p><p>&bull; فرط حساسية العين للضوء، وجفاف العين، زيادة الدموع، احمرار في العينين.</p><p>&bull; الإحساس بالدوار، الرنين في الأذن، وألم الأذن.</p><p>&bull; الرجفان الأذيني (إيقاع غير طبيعي للقلب)، انقطاع في التوصيل بين الجزأين العلوي والسفلي للقلب، توصيل كهربائي غير طبيعي للقلب وإطالة أمد الفترة الفاصلة QT من القلب، وبطء معدل ضربات القلب ، تتبع كهربائي غير طبيعي للقلب (ECG)، وخفقان الصدر.</p><p>&bull; انخفاض ضغط الدم، وانخفاض ضغط الدم عند الوقوف (وبالتالي، فإن بعض الأشخاص الذين يتناولون ريسبال قد يشعرون بالإغماء، بالدوار، أو قد يفقدون الوعي عند الوقوف أو الجلوس فجأة، أو تورد الوجه).</p><p>&bull; الإلتهاب الرئوي الناجم عن استنشاق المواد الغذائية، احتقان الرئة، احتقان ممرات التنفس، أصوات طقطقة في الرئة ، صفير، اضطراب الصوت، اضطراب ممرات التنفس.</p><p>&bull; إلتهاب المعدة أو الأمعاء، سلس البراز، البراز الصلب جداً، صعوبة في البلع، فرط إخراج الغازات.</p><p>&bull; شرى (أو &quot;طفح القراص&quot;)، الحكة، فقدان الشعر، سماكة في الجلد، الأكزيما، جفاف الجلد، اختلاف لون الجلد، حب الشباب، حكة في فروة الرأس أو الجلد، اضطرابات الجلد، وآفة الجلد.</p><p>&bull; زيادة مستوى الكرياتين فسفوكيناز في الدم، وهو الأنزيم الذي يفرز عند انهيار العضلات.</p><p>&bull; وقفة غير طبيعية، وتصلب المفاصل، تورم المفاصل، ضعف العضلات، وآلام في الرقبة.</p><p>&bull; التبول المتكرر، عدم القدرة على التبول، ألم عند التبول.</p><p>&bull; عدم القدرة على الإنتصاب، واضطراب القذف.</p><p>&bull; انقطاع الطمث أو مشاكل أخرى في الدورة الشهرية (للإناث).</p><p>&bull; نمو الثدي في الرجال، تسرب الحليب من الثديين، والخلل الوظيفي الجنسي، ألم الثدي، وعدم الراحة في الثدي، افرازات مهبلية.</p><p>&bull; تورم في الوجه، الفم، العينين، أو الشفاه.</p><p>&bull; قشعريرة، زيادة في درجة حرارة الجسم.</p><p>&bull; تغير في طريقة المشي.</p><p>&bull; الشعور بالعطش، والشعور بالإعياء، وعدم الراحة في الصدر، وعدم الراحة.</p><p>&bull; زيادة ناقلات الأمين الكبدية في الدم، وزيادة إنزيم الكبدGGT في الدم، زيادة إنزيمات الكبد في الدم.</p><p>&bull; ألم.</p><p>نادرة الحدوث (من الممكن أن تصيب لغاية شخص لكل 1000 شخص):</p><p>&bull; العدوى.</p><p>&bull; إفراز غير صحيح للهرمون الذي يتحكم في حجم البول.</p><p>&bull; السكر في البول، وانخفاض نسبة السكر في الدم وارتفاع الدهون الثلاثية في الدم (الدهون).</p><p>&bull; عدم وجود العاطفة، عدم القدرة على الوصول إلى النشوة الجنسية.</p><p>&bull; متلازمة مضادات الذهان الخبيثة (الارتباك، وانخفاض أو فقدان الوعي، حمى شديدة، وتصلب شديد في العضلات).</p><p>&bull; مشاكل في الأوعية الدموية الدماغية.</p><p>&bull; غيبوبة بسبب مرض السكري الغير منضبط.</p><p>&bull; هز الرأس.</p><p>&bull; الجلوكوما (ارتفاع الضغط داخل مقلة العين)، مشاكل في حركة العين، دوران العين، تقشر هامش الجفن.</p><p>&bull; مشاكل في العين خلال جراحة اعتمام العدسة. من الممكن أن تحدث حالة متلازمة القزحية المرنة (IFIS) أثناء&nbsp; اجراء العملية&nbsp; إذا كنت تتناول أو تناولت ريسبال. إذا كنت بحاجة إلى جراحة اعتمام العدسة، عليك اعلام طبيب العيون بأنك تتناول أو تناولت ريسبال.</p><p>&bull; انخفاض خطير في أعداد نوع معين من خلايا الدم البيضاء اللازمة لمكافحة العدوى في الدم.</p><p>&bull; رد فعل تحسسي شديد يتميز بالحمى، تورم الفم، الوجه، الشفاه أو اللسان، وضيق في التنفس، والحكة، الطفح الجلدي و أحياناً انخفاض في ضغط الدم.</p><p>&bull; الإفراط في تناول الماء بشكل خطير.</p><p>&bull; عدم انتظام ضربات القلب.</p><p>&bull; تجلط الدم في الساقين، تجلط الدم في الرئتين.</p><p>&bull; مشاكل تنفسية أثناء النوم (توقف التنفس أثناء النوم)، التنفس السريع، التنفس الضحل.</p><p>&bull; إلتهاب البنكرياس، وانسداد في الأمعاء.</p><p>&bull; تورم اللسان، تشقق الشفتين، طفح على الجلد متعلق بتناول الدواء.</p><p>&bull; قشرة الرأس.</p><p>&bull; انحلال ألياف العضلات وآلام في العضلات (انحلال الربيدات).</p><p>&bull; تأخير في الدورة الشهرية، تضخم الغدد في الثدي، تضخم الثدي وإفرازات من الثدي.</p><p>&bull; ارتفاع مستوى الأنسولين في الدم (الهرمون الذي يتحكم في مستويات السكر في الدم).</p><p>&bull; القساح ( انتصاب القضيب لفترة طويلة الذي قد يتطلب العلاج الجراحي).</p><p>&bull; تصلب الجلد.</p><p>&bull; انخفاض درجة حرارة الجسم، برودة في الذراعين والساقين.</p><p>&bull; أعراض انسحاب الدواء.</p><p>&bull; اصفرار الجلد والعينين (اليرقان).</p><p>نادرة جداً (من الممكن أن تصيب لغاية شخص لكل&nbsp; 10,000 شخص):</p><p>&bull; مضاعفات مرض السكري غير المنضبط التي تهدد الحياة.</p><p>&bull; رد فعل تحسسي خطير مع تورم في الحلق، والذي يؤدي إلى صعوبة في التنفس.</p><p>&bull; قلة حركة العضلات في الأمعاء مما قد يسبب انسداد الأمعاء.</p><p>يمكن توقع الآثار الجانبية التالية عند استخدام ريسبال حيث أنها حدثت عند استخدام دواء آخر يسمى الباليبيريدون وهو دواء مشابه جداً لرسبريدون، وهي: سرعة ضربات القلب عند الوقوف.</p><p>آثار جانبية إضافية في الأطفال والمراهقين</p><p>الآثار الجانبية عند الأطفال من المتوقع أن تكون مشابهة لتلك الموجودة في البالغين بشكل عام.</p><p>تم الإبلاغ عن الآثار الجانبية التالية في أكثر الأحيان في الأطفال والمراهقين (5 إلى 17 سنة) أكثر من البالغين: الشعور بالنعاس، أو قلة التيقظ، الإجهاد (التعب)، الصداع، زيادة الشهية، القيء، أعراض نزلات البرد الشائعة، احتقان الأنف، ألم في البطن، الدوخة، السعال، الحمى، الرعشة (الهزة)، الإسهال، وسلس البول (عدم التحكم في التبول). إذا أصابتك أي آثار جانبية، تحدث مع الطبيب أو الصيدلاني. وهذه تشمل الآثار الجانبية التي لم يرد ذكرها في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;&nbsp; يحفظ بعيداً عن متناول الأطفال.</p><p>&bull; لا تستخدم محلول ريسبال بعد انتهاء فترة الصلاحية&nbsp; المذكورة على اللاصق الداخلي و العبوة الخارجية.</p><p>&bull; لا يتطلب هذا المنتج الدوائي أي ظروف تخزين خاصة.</p><p>&bull; لا تستخدم ريسبال عند ملاحظة أي علامة تلف عليه.</p><p>&bull; يحفظ في درجة حرارة الغرفة أقل من 30 oم.</p><p>&bull; لا تستخدم محلول ريسبال بعد فتح الزجاجة لأكثر من 3 أشهر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>محلول ريسبال 1ملغم/1مل يحتوي على 1 ملغم رسبريدون لكل 1 مل من المحلول.</p><p>المكونات الأخرى هي: حمض بنزويك/ سوربيتول سائل 70%/&nbsp; صوديوم سكارين/ حمض الستريك/ ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>الشكل الصيدلاني: محلول</p><p>حجم عبوة محلول ريسبال: 100 مل</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الأردنية السويدية للمنتجات الطبية و التعقيم.</p><p>صندوق بريد 851831&nbsp; عمان 11185&nbsp; الأردن</p><p>الايميل: joswe@go.com.jo</p><p>www.joswe.com</p><p>هاتف: +962 6 5728327 ،+962 6 5859765</p><p>فاكس: +962 6 5728326 ،+962 6 5814526</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في  3/2019 ؛ رقم المراجعة R0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Respal Oral® Solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 1ml contains 1mg Risperidone.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Respal is indicated for the treatment of schizophrenia.</p><p>Respal is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.</p><p>Respal is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.</p><p>Respal is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>Schizophrenia</u></p><p><em>Adults</em></p><p>RESPAL may be given once daily or twice daily.</p><p>Patients should start with 2 mg/day risperidone. The dosage may be increased on the second day to 4 mg. Subsequently, the dosage can be maintained unchanged, or further individualised, if needed. Most patients will benefit from daily doses between 4 and 6 mg. In some patients, a slower titration phase and a lower starting and maintenance dose may be appropriate.</p><p>Doses above 10 mg/day have not demonstrated superior efficacy to lower doses and may cause increased incidence of extrapyramidal symptoms. Safety of doses above 16 mg/day has not been evaluated, and are therefore not recommended.</p><p><em>Elderly</em></p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily.</p><p><em>Paediatric population</em></p><p>Risperidone is not recommended for use in children below age 18 with schizophrenia due to a lack of data on efficacy.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Manic episodes in bipolar disorder</u></p><p><em>Adults</em></p><p>RESPAL should be administered on a once daily schedule, starting with 2 mg risperidone. Dosage adjustments, if indicated, should occur at intervals of not less than 24 hours and in dosage increments of 1 mg per day. Risperidone can be administered in flexible doses over a range of 1 to 6 mg per day to optimize each patient&#39;s level of efficacy and tolerability. Daily doses over 6 mg risperidone have not been investigated in patients with manic episodes.</p><p>As with all symptomatic treatments, the continued use of RESPAL must be evaluated and justified on an ongoing basis.</p><p><em>Elderly</em></p><p>A starting dose of 0.5 mg twice daily is recommended. This dosage can be individually adjusted with 0.5 mg twice daily increments to 1 to 2 mg twice daily. Since clinical experience in elderly is limited, caution should be exercised.</p><p><em>Paediatric population</em></p><p>Risperidone is not recommended for use in children below age 18 with bipolar mania due to a lack of data on efficacy.</p><p>&nbsp;</p><p><u>Persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia</u></p><p>A starting dose of 0.25 mg twice daily is recommended. This dosage can be individually adjusted by increments of 0.25 mg twice daily, not more frequently than every other day, if needed. The optimum dose is 0.5 mg twice daily for most patients. Some patients, however, may benefit from doses up to 1 mg twice daily.</p><p>RESPAL should not be used more than 6 weeks in patients with persistent aggression in Alzheimer&#39;s dementia. During treatment, patients must be evaluated frequently and regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><u>Conduct disorder</u></p><p><em>Children and adolescents from 5 to 18 years of age</em></p><p>For subjects &ge;50 kg, a starting dose of 0.5 mg once daily is recommended. This dosage can be individually adjusted by increments of 0.5 mg once daily not more frequently than every other day, if needed. The optimum dose is 1 mg once daily for most patients. Some patients, however, may benefit from 0.5 mg once daily while others may require 1.5 mg once daily. For subjects &lt;50 kg, a starting dose of 0.25 mg once daily is recommended. This dosage can be individually adjusted by increments of 0.25 mg once daily not more frequently than every other day, if needed. The optimum dose is 0.5 mg once daily for most patients. Some patients, however, may benefit from 0.25 mg once daily while others may require 0.75 mg once daily.</p><p>As with all symptomatic treatments, the continued use of RESPAL must be evaluated and justified on an ongoing basis.</p><p>RESPAL is not recommended in children less than 5 years of age, as there is no experience in children less than 5 years of age with this disorder.</p><p><u>Renal and hepatic impairment</u></p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than in adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone.</p><p>Irrespective of the indication, starting and consecutive dosing should be halved, and dose titration should be slower for patients with renal or hepatic impairment.</p><p>RESPAL should be used with caution in these groups of patients.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>RESPAL is for oral use. Food does not affect the absorption of RESPAL.</p><p>Upon discontinuation, gradual withdrawal is advised. Acute withdrawal symptoms, including nausea, vomiting, sweating, and insomnia have very rarely been described after abrupt cessation of high doses of antipsychotic medicines (see section 4.8). Recurrence of psychotic symptoms may also occur, and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) has been reported.</p><p><em>Switching from other antipsychotics.</em></p><p>When medically appropriate, gradual discontinuation of the previous treatment while RESPAL therapy is initiated is recommended. Also, if medically appropriate, when switching patients from depot antipsychotics, initiate RESPAL therapy in place of the next scheduled injection. The need for continuing existing anti-Parkinson medicines should be re-evaluated periodically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Elderly patients with dementia</u></p><p><em>Increased mortality in elderly people with dementia</em></p><p>In a meta-analysis of 17 controlled trials of atypical antipsychotics, including RESPAL, elderly patients with dementia treated with atypical antipsychotics have an increased mortality compared to placebo. In placebo-controlled trials with oral RESPAL in this population, the incidence of mortality was 4.0% for RESPAL-treated patients compared to 3.1% for placebo-treated patients. The odds ratio (95% exact confidence interval) was 1.21 (0.7, 2.1). The mean age (range) of patients who died was 86 years (range 67-100). Data from two large observational studies showed that elderly people with dementia who are treated with conventional antipsychotics are also at a small increased risk of death compared with those who are not treated. There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p><p><em>Concomitant use with furosemide</em></p><p>In the RESPAL placebo-controlled trials in elderly patients with dementia, a higher incidence of mortality was observed in patients treated with furosemide plus risperidone (7.3%; mean age 89 years, range 75-97) when compared to patients treated with risperidone alone (3.1%; mean age 84 years, range 70-96) or furosemide alone (4.1%; mean age 80 years, range 67-90). The increase in mortality in patients treated with furosemide plus risperidone was observed in two of the four clinical trials. Concomitant use of risperidone with other diuretics (mainly thiazide diuretics used in low dose) was not associated with similar findings.</p><p>No pathophysiological mechanism has been identified to explain this finding, and no consistent pattern for cause of death observed. Nevertheless, caution should be exercised and the risks and benefits of this combination or co-treatment with other potent diuretics should be considered prior to the decision to use. There was no increased incidence of mortality among patients taking other diuretics as concomitant treatment with risperidone. Irrespective of treatment, dehydration was an overall risk factor for mortality and should therefore be carefully avoided in elderly patients with dementia.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cerebrovascular Adverse Events (CVAE) </u></p><p>An approximately 3-fold increased risk of cerebrovascular adverse events have been seen in randomised placebo controlled clinical trials in the dementia population with some atypical antipsychotics. The pooled data from six placebo-controlled studies with RESPAL in mainly elderly patients (&gt;65 years of age) with dementia showed that CVAEs (serious and non-serious, combined) occurred in 3.3% (33/1009) of patients treated with risperidone and 1.2% (8/712) of patients treated with placebo. The odds ratio (95% exact confidence interval) was 2.96 (1.34, 7.50). The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. RESPAL should be used with caution in patients with risk factors for stroke.</p><p>The risk of CVAEs was significantly higher in patients with mixed or vascular type of dementia when compared to Alzheimer&#39;s dementia. Therefore, patients with other types of dementias than Alzheimer&#39;s should not be treated with risperidone.</p><p>Physicians are advised to assess the risks and benefits of the use of RESPAL in elderly patients with dementia, taking into account risk predictors for stroke in the individual patient. Patients/caregivers should be cautioned to immediately report signs and symptoms of potential CVAEs such as sudden weakness or numbness in the face, arms or legs, and speech or vision problems. All treatment options should be considered without delay, including discontinuation of risperidone.</p><p>RESPAL should only be used short term for persistent aggression in patients with moderate to severe Alzheimer&#39;s dementia to supplement non-pharmacological approaches which have had limited or no efficacy and when there is potential risk of harm to self or others.</p><p>Patients should be reassessed regularly, and the need for continuing treatment reassessed.</p><p>&nbsp;</p><p><u>Orthostatic hypotension</u></p><p>Due to the alpha-blocking activity of risperidone, (orthostatic) hypotension can occur, especially during the initial dose-titration period. Clinically significant hypotension has been observed postmarketing with concomitant use of risperidone and antihypertensive treatment. RESPAL should be used with caution in patients with known cardiovascular disease (e.g., heart failure, myocardial infarction, conduction abnormalities, dehydration, hypovolemia, or cerebrovascular disease), and the dosage should be gradually titrated as recommended (see section 4.2). A dose reduction should be considered if hypotension occurs.</p><p>&nbsp;</p><p><u>Leukopenia, neutropenia, and agranulocytosis</u></p><p>Events of leucopenia, neutropenia and agranulocytosis have been reported with antipsychotic agents, including RESPAL. Agranulocytosis has been reported very rarely (&lt; 1/10,000 patients) during post-marketing surveillance.</p><p>Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of RESPAL should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p><p>Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count &lt; 1 X 10<sup>9</sup>/L) should discontinue RESPAL and have their WBC followed until recovery.</p><p>&nbsp;</p><p><u>Tardive dyskinesia/extrapyramidal symptoms (TD/EPS)</u></p><p>Medicines with dopamine receptor antagonistic properties have been associated with the induction of tardive dyskinesia characterised by rhythmical involuntary movements, predominantly of the tongue and/or face. The onset of extrapyramidal symptoms is a risk factor for tardive dyskinesia. If signs and symptoms of tardive dyskinesia appear, the discontinuation of all antipsychotics should be considered.</p><p>&nbsp;</p><p><u>Neuroleptic malignant syndrome (NMS)</u></p><p>Neuroleptic Malignant Syndrome, characterised by hyperthermia, muscle rigidity, autonomic instability, altered consciousness and elevated serum creatine phosphokinase levels has been reported to occur with antipsychotics. Additional signs may include myoglobinuria (rhabdomyolysis) and acute renal failure. In this event, all antipsychotics, including RESPAL, should be discontinued.</p><p>&nbsp;</p><p><u>Parkinson&#39;s disease and dementia with Lewy bodies</u></p><p>Physicians should weigh the risks versus the benefits when prescribing antipsychotics, including RESPAL, to patients with Parkinson&#39;s Disease or Dementia with Lewy Bodies (DLB). Parkinson&#39;s Disease may worsen with risperidone. Both groups may be at increased risk of Neuroleptic Malignant Syndrome as well as having an increased sensitivity to antipsychotic medicinal products; these patients were excluded from clinical trials. Manifestation of this increased sensitivity can include confusion, obtundation, postural instability with frequent falls, in addition to extrapyramidal symptoms.</p><p><u>Hyperglycaemia and diabetes mellitus</u></p><p>Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes have been reported during treatment with RESPAL. In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Association with ketoacidosis has been reported very rarely and rarely with diabetic coma. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines. Patients treated with any atypical antipsychotic, including RESPAL, should be monitored for symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia and weakness) and patients with diabetes mellitus should be monitored regularly for worsening of glucose control.</p><p>&nbsp;</p><p><u>Weight gain</u></p><p>Significant weight gain has been reported with RESPAL use. Weight should be monitored regularly.</p><p>&nbsp;</p><p><u>Hyperprolactinaemia</u></p><p>Hyperprolactinaemia is a common side-effect of treatment with RESPAL. Evaluation of the prolactin plasma level is recommended in patients with evidence of possible prolactin-related side-effects (e.g. gynaecomastia, menstrual disorders, anovulation, fertility disorder, decreased libido, erectile dysfunction, and galactorrhea).</p><p>Tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Although no clear association with the administration of antipsychotics has so far been demonstrated in clinical and epidemiological studies, caution is recommended in patients with relevant medical history. RESPAL should be used with caution in patients with pre-existing hyperprolactinaemia and in patients with possible prolactin-dependent tumours.</p><p>&nbsp;</p><p><u>QT prolongation</u></p><p>QT prolongation has very rarely been reported postmarketing. As with other antipsychotics, caution should be exercised when risperidone is prescribed in patients with known cardiovascular disease, family history of QT prolongation, bradycardia, or electrolyte disturbances (hypokalaemia, hypomagnesaemia), as it may increase the risk of arrhythmogenic effects, and in concomitant use with medicines known to prolong the QT interval.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>RESPAL should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.</p><p>&nbsp;</p><p><u>Priapism </u></p><p>Priapism may occur with RESPAL treatment due to its alpha-adrenergic blocking effects.</p><p>&nbsp;</p><p><u>Body temperature regulation </u></p><p>Disruption of the body&#39;s ability to reduce core body temperature has been attributed to antipsychotic medicines. Appropriate care is advised when prescribing RESPAL to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant treatment with anticholinergic activity, or being subject to dehydration.</p><p>&nbsp;</p><p><u>Antiemetic effect</u></p><p>An antiemetic effect was observed in preclinical studies with risperidone. This effect, if it occurs in humans, may mask the signs and symptoms of overdosage with certain medicines or of conditions such as intestinal obstruction, Reye&#39;s syndrome, and brain tumour.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>Patients with renal impairment have less ability to eliminate the active antipsychotic fraction than adults with normal renal function. Patients with impaired hepatic function have increases in plasma concentration of the free fraction of risperidone (see section 4.2).</p><p>&nbsp;</p><p><u>Venous thromboembolism</u></p><p>Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with RESPAL and preventative measures undertaken.</p><p>&nbsp;</p><p><u>Intraoperative Floppy Iris Syndrome</u></p><p>Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in patients treated with medicines with alpha1a-adrenergic antagonist effect, including RESPAL (see Section 4.8).</p><p>IFIS may increase the risk of eye complications during and after the operation. Current or past use of medicines with alpha1a-adrenergic antagonist effect should be made known to the ophthalmic surgeon in advance of surgery. The potential benefit of stopping alpha1 blocking therapy prior to cataract surgery has not been established and must be weighed against the risk of stopping the antipsychotic therapy.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Before risperidone is prescribed to a child or adolescent with conduct disorder they should be fully assessed for physical and social causes of the aggressive behaviour such as pain or inappropriate environmental demands.</p><p>The sedative effect of risperidone should be closely monitored in this population because of possible consequences on learning ability. A change in the time of administration of risperidone could improve the impact of the sedation on attention faculties of children and adolescents.</p><p>Risperidone was associated with mean increases in body weight and body mass index (BMI). Baseline weight measurement prior to treatment and regular weight monitoring are recommended. Changes in height in the long-term open-label extension studies were within expected age-appropriate norms. The effect of long-term risperidone treatment on sexual maturation and height has not been adequately studied.</p><p>Because of the potential effects of prolonged hyperprolactinemia on growth and sexual maturation in children and adolescents, regular clinical evaluation of endocrinological status should be considered, including measurements of height, weight, sexual maturation, monitoring of menstrual functioning, and other potential prolactin-related effects.</p><p>Results from a small post-marketing observational study showed that risperidone-exposed subjects between the ages of 8-16 years were on average approximately 3.0 to 4.8 cm taller than those who received other atypical anti-psychotic medications. This study was not adequate to determine whether exposure to risperidone had any impact on final adult height, or whether the result was due to a direct effect of risperidone on bone growth, or the effect of the underlying disease itself on bone growth, or the result of better control of the underlying disease with resulting increase in linear growth.</p><p>During treatment with risperidone regular examination for extrapyramidal symptoms and other movement disorders should also be conducted.</p><p>For specific posology recommendations in children and adolescents see Section 4.2.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic-related Interactions</u></p><p><em>Drugs known to prolong the QT interval</em></p><p>As with other antipsychotics, caution is advised when prescribing risperidone with medicinal products known to prolong the QT interval, such as antiarrhythmics (e.g., quinidine, dysopiramide, procainamide, propafenone, amiodarone, sotalol), tricyclic antidepressants (i.e., amitriptyline), tetracyclic antidepressants (i.e., maprotiline), some antihistamines, other antipsychotics, some antimalarials (i.e., quinine and mefloquine), and with medicines causing electrolyte imbalance (hypokalaemia, hypomagnesiaemia), bradycardia, or those which inhibit the hepatic metabolism of risperidone. This list is indicative and not exhaustive.</p><p><em>Centrally-Acting Drugs and Alcohol</em></p><p>Risperidone should be used with caution in combination with other centrally-acting substances notably including alcohol, opiates, antihistamines and benzodiazepines due to the increased risk of sedation.</p><p><em>Levodopa and Dopamine Agonists</em></p><p>RESPAL may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson&#39;s disease, the lowest effective dose of each treatment should be prescribed.</p><p><em>Drugs with Hypotensive Effect</em></p><p>Clinically significant hypotension has been observed postmarketing with concomitant use of risperidone and antihypertensive treatment.</p><p><em>Paliperidone</em></p><p>Concomitant use of oral RESPAL with paliperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive active antipsychotic fraction exposure.</p><p><u>Pharmacokinetic-related Interactions</u></p><p>Food does not affect the absorption of RESPAL.</p><p>Risperidone is mainly metabolized through CYP2D6, and to a lesser extent through CYP3A4. Both risperidone and its active metabolite 9-hydroxyrisperidone are substrates of P-glycoprotein (P-gp). Substances that modify CYP2D6 activity, or substances strongly inhibiting or inducing CYP3A4 and/or P-gp activity, may influence the pharmacokinetics of the risperidone active antipsychotic fraction.</p><p><em>Strong CYP2D6 Inhibitors</em></p><p>Co-administration of RESPAL with a strong CYP2D6 inhibitor may increase the plasma concentrations of risperidone, but less so of the active antipsychotic fraction. Higher doses of a strong CYP2D6 inhibitor may elevate concentrations of the risperidone active antipsychotic fraction (e.g., paroxetine, see below). It is expected that other CYP 2D6 inhibitors, such as quinidine, may affect the plasma concentrations of risperidone in a similar way. When concomitant paroxetine, quinidine, or another strong CYP2D6 inhibitor, especially at higher doses, is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL.</p><p><em>CYP3A4 and/or P-gp Inhibitors</em></p><p>Co-administration of RESPAL with a strong CYP3A4 and/or P-gp inhibitor may substantially elevate plasma concentrations of the risperidone active antipsychotic fraction. When concomitant itraconazole or another strong CYP3A4 and/or P-gp inhibitor is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL.</p><p><em>CYP3A4 and/or P-gp Inducers</em></p><p>Co-administration of RESPAL with a strong CYP3A4 and/or P-gp inducer may decrease the plasma concentrations of the risperidone active antipsychotic fraction. When concomitant carbamazepine or another strong CYP3A4 and/or P-gp inducer is initiated or discontinued, the physician should re-evaluate the dosing of RESPAL. CYP3A4 inducers exert their effect in a time-dependent manner, and may take at least 2 weeks to reach maximal effect after introduction. Conversely, on discontinuation, CYP3A4 induction may take at least 2 weeks to decline.</p><p><em>Highly Protein-bound Drugs</em></p><p>When RESPAL is taken together with highly protein-bound drugs, there is no clinically relevant displacement of either drug from the plasma proteins.</p><p>When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism and the possible need to adjust dosage.</p><p><u>Paediatric Population</u></p><p>Interaction studies have only been performed in adults. The relevance of the results from these studies in paediatric patients is unknown.</p><p>The combined use of psychostimulants (e.g., methylphenidate) with RESPAL in children and adolescents did not alter the pharmacokinetics and efficacy of RESPAL.</p><p><u>Examples</u></p><p>Examples of drugs that may potentially interact or that were shown not to interact with risperidone are listed below:</p><p>&nbsp;</p><p><u>Effect of other medicinal products on the pharmacokinetics of risperidone</u></p><p>Antibacterials:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythromycin, a moderate CYP3A4 inhibitor and P-gp inhibitor, does not change the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin, a strong CYP3A4 inducer and a P-gp inducer, decreased the plasma concentrations of the active antipsychotic fraction.</p><p>&nbsp;</p><p>&nbsp;</p><p>Anticholinesterases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Donepezil and galantamine, both CYP2D6 and CYP3A4 substrates, do not show a clinically relevant effect on the pharmacokinetics of risperidone and the active antipsychotic fraction.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Antiepileptics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbamazepine, a strong CYP3A4 inducer and a P-gp inducer, has been shown to decrease the plasma concentrations of the active antipsychotic fraction of risperidone. Similar effects may be observed with e.g. phenytoin and phenobarbital which also induce CYP 3A4 hepatic enzyme, as well as P-glycoprotein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Topiramate modestly reduced the bioavailability of risperidone, but not that of the active antipsychotic fraction. Therefore, this interaction is unlikely to be of clinical significance.</p><p>Antifungals:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itraconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200 mg/day increased the plasma concentrations of the active antipsychotic fraction by about 70%, at risperidone doses of 2 to 8 mg/day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, a strong CYP3A4 inhibitor and a P-gp inhibitor, at a dosage of 200mg/day increased the plasma concentrations of risperidone and decreased the plasma concentrations of 9-hydroxyrisperidone.</p><p>Antipsychotics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenothiazines may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>Antivirals:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protease inhibitors: No formal study data are available; however, since ritonavir is a strong CYP3A4 inhibitor and a weak CYP2D6 inhibitor, ritonavir and ritonavir-boosted protease inhibitor potentially raise concentrations of the risperidone active antipsychotic fraction.</p><p>Beta blockers:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some beta-blockers may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction.</p><p>Calcium channel blockers:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verapamil, a moderate inhibitor of CYP3A4 and an inhibitor of P-gp, increases the plasma concentration of risperidone and the active antipsychotic fraction.</p><p>Gastrointestinal drugs:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; H<sub>2</sub>-receptor antagonists: Cimetidine and ranitidine, both weak inhibitors of CYP2D6 and CYP3A4, increased the bioavailability of risperidone, but only marginally that of the active antipsychotic fraction.</p><p>SSRIs and Tricyclic antidepressants:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluoxetine, a strong CYP2D6 inhibitor, increases the plasma concentration of risperidone, but less so of the active antipsychotic fraction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paroxetine, a strong CYP2D6 inhibitor, increases the plasma concentrations of risperidone, but, at dosages up to 20 mg/day, less so of the active antipsychotic fraction. However, higher doses of paroxetine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tricyclic antidepressants may increase the plasma concentrations of risperidone but not those of the active antipsychotic fraction. Amitriptyline does not affect the pharmacokinetics of risperidone or the active antipsychotic fraction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sertraline, a weak inhibitor of CYP2D6, and fluvoxamine, a weak inhibitor of CYP3A4, at dosages up to 100 mg/day are not associated with clinically significant changes in concentrations of the risperidone active antipsychotic fraction. However, doses higher than 100 mg/day of sertraline or fluvoxamine may elevate concentrations of the risperidone active antipsychotic fraction.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effect of risperidone on the pharmacokinetics of other medicinal products</u></p><p>Antiepileptics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risperidone does not show a clinically relevant effect on the pharmacokinetics of valproate or topiramate.</p><p>Antipsychotics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aripiprazole, a CYP2D6 and CYP3A4 substrate: Risperidone tablets or injections did not affect the pharmacokinetics of the sum of aripiprazole and its active metabolite, dehydroaripiprazole.</p><p>Digitalis glycosides:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risperidone does not show a clinically relevant effect on the pharmacokinetics of digoxin.</p><p>Lithium:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Risperidone does not show a clinically relevant effect on the pharmacokinetics of lithium.</p><p>&nbsp;</p><p><u>Concomitant use of risperidone with furosemide</u></p><p>See section 4.4 regarding increased mortality in elderly patients with dementia concomitantly receiving furosemide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of risperidone in pregnant women. Risperidone was not teratogenic in animal studies but other types of reproductive toxicity were seen (see section 5.3). The potential risk for humans is unknown.</p><p>Neonates exposed to antipsychotics (including RESPAL) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>RESPAL should not be used during pregnancy unless clearly necessary. If discontinuation during pregnancy is necessary, it should not be done abruptly.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>In animal studies, risperidone and 9-hydroxy-risperidone are excreted in the milk. It has been demonstrated that risperidone and 9-hydroxy-risperidone are also excreted in human breast milk in small quantities. There are no data available on adverse reactions in breast-feeding infants. Therefore, the advantage of breast-feeding should be weighed against the potential risks for the child.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>As with other drugs that antagonize dopamine D2 receptors, RESPAL elevates prolactin level. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients.</p><p>There were no relevant effects observed in the non-clinical studies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESPAL can have minor or moderate influence on the ability to drive and use machines due to potential nervous system and visual effects (see section 4.8). Therefore, patients should be advised not to drive or operate machinery until their individual susceptibility is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse drug reactions (ADRs) (incidence &ge;10%) are: Parkinsonism, sedation/somnolence, headache and insomnia.</p><p>The ADRs that appeared to be dose-related included parkinsonism and akathisia.</p><p>The following are all the ADRs that were reported in clinical trials and postmarketing experience with risperidone by frequency category estimated from RESPAL clinical trials. The following terms and frequencies are applied: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td colspan="5" style="vertical-align:top"><p><strong>Adverse Drug Reaction</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p><strong>Very Common </strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>pneumonia, bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, ear infection, influenza</p></td><td style="vertical-align:top"><p>respiratory tract infection, cystitis, eye infection, tonsillitis, onychomycosis, cellulitis localised infection, viral infection, acarodermatitis</p></td><td style="vertical-align:top"><p>infection</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>neutropenia, white blood cell count decreased, thrombocytopenia, anaemia, haematocrit decreased, eosinophil count increased</p></td><td style="vertical-align:top"><p>agranulocytosis<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypersensitivity</p></td><td style="vertical-align:top"><p>anaphylactic reaction<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hyperprolactinaemia<sup> a</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>inappropriate antidiuretic hormone secretion, glucose urine present</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>weight increased, increased appetite, decreased appetite</p></td><td style="vertical-align:top"><p>diabetes mellitus<sup> b</sup>, hyperglycaemia, polydipsia, weight decreased, anorexia, blood cholesterol increased</p></td><td style="vertical-align:top"><p>water intoxication<sup>c</sup>, hypoglycemia, hyperinsulinaemia<sup>c</sup>, blood triglycerides increased</p></td><td style="vertical-align:top"><p>diabetic ketoacidosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>insomnia<sup>d</sup></p></td><td style="vertical-align:top"><p>sleep disorder, agitation, depression, anxiety</p></td><td style="vertical-align:top"><p>mania, confusional state, libido decreased, nervousness, nightmare</p></td><td style="vertical-align:top"><p>blunted affect, anorgasmia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>sedation/ somnolence, parkinsonism<sup> d</sup>, headache</p></td><td style="vertical-align:top"><p>akathisia<sup>d</sup>, dystonia<sup>d</sup>, dizziness, dyskinesia<sup>d</sup>, tremor</p></td><td style="vertical-align:top"><p>tardive dyskinesia, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsion<sup>d</sup>, syncope, psychomotor hyperactivity, balance disorder, coordination abnormal, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoaesthesia, paraesthesia</p></td><td style="vertical-align:top"><p>neuroleptic malignant syndrome, cerebrovascular disorder, diabetic coma, head titubation</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vision blurred, conjunctivitis</p></td><td style="vertical-align:top"><p>photophobia, dry eye, lacrimation increased, ocular hyperaemia</p></td><td style="vertical-align:top"><p>glaucoma, eye movement disorder, eye rolling, eyelid margin crusting, floppy iris syndrome (intraoperative)<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vertigo, tinnitus, ear pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>tachycardia</p></td><td style="vertical-align:top"><p>atrial fibrillation, atrioventricular block, conduction disorder, electrocardiogram QT prolonged, bradycardia, electrocardiogram abnormal, palpitations</p></td><td style="vertical-align:top"><p>sinus arrhythmia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypertension</p></td><td style="vertical-align:top"><p>hypotension, orthostatic hypotension, flushing</p></td><td style="vertical-align:top"><p>pulmonary embolism, venous thrombosis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>dyspnoea, pharyngolaryngeal pain, cough, epistaxis, nasal congestion</p></td><td style="vertical-align:top"><p>pneumonia aspiration, pulmonary congestion, respiratory tract congestion, rales, wheezing, dysphonia, respiratory disorder</p></td><td style="vertical-align:top"><p>sleep apnoea syndrome, hyperventilation</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>abdominal pain, abdominal discomfort, vomiting, nausea, constipation, diarrhoea, dyspepsia, dry mouth, toothache</p></td><td style="vertical-align:top"><p>faecal incontinence, faecaloma, gastroenteritis, dysphagia, flatulence</p></td><td style="vertical-align:top"><p>pancreatitis, intestinal obstruction, swollen tongue, cheilitis</p></td><td style="vertical-align:top"><p>ileus</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>rash, erythema</p></td><td style="vertical-align:top"><p>urticaria, pruritus, alopecia, hyperkeratosis, eczema, dry skin, skin discolouration, acne, seborrhoeic dermatitis, skin disorder, skin lesion</p></td><td style="vertical-align:top"><p>drug eruption, dandruff</p></td><td style="vertical-align:top"><p>angioedema</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>muscle spasms, musculoskeletal pain, back pain, arthralgia</p></td><td style="vertical-align:top"><p>blood creatine phosphokinase increased, posture abnormal, joint stiffness, joint swelling muscular weakness, neck pain</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>urinary incontinence</p></td><td style="vertical-align:top"><p>pollakiuria, urinary retention, dysuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Pregnancy, puerperium, and neonatal conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>drug withdrawal syndrome neonatal<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>erectile dysfunction, ejaculation disorder, amenorrhoea, menstrual disorder<sup>d</sup>, gynaecomastia, galactorrhoea, sexual dysfunction, breast pain, breast discomfort, vaginal discharge</p></td><td style="vertical-align:top"><p>priapism<sup>c</sup>, menstruation delayed, breast engorgement, breast enlargement, breast discharge</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>oedema<sup>d</sup>, pyrexia, chest pain, asthenia, fatigue, pain</p></td><td style="vertical-align:top"><p>face oedema, chills, body temperature increased, gait abnormal, thirst, chest discomfort, malaise, feeling abnormal, discomfort</p></td><td style="vertical-align:top"><p>hypothermia, body temperature decreased, peripheral coldness, drug withdrawal syndrome, induration<sup>c</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>transaminases increased, gamma-glutamyltransferase increased, hepatic enzyme increased</p></td><td style="vertical-align:top"><p>jaundice</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>fall</p></td><td style="vertical-align:top"><p>procedural pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>a</sup> Hyperprolactinemia can in some cases lead to gynaecomastia, menstrual disturbances, amenorrhoea, anovulation, galactorrhea, fertility disorder, decreased libido, erectile dysfunction.</p><p><sup>b</sup> In placebo-controlled trials diabetes mellitus was reported in 0.18% in risperidone-treated subjects compared to a rate of 0.11% in placebo group. Overall incidence from all clinical trials was 0.43% in all risperidone-treated subjects.</p><p><sup>c</sup> Not observed in RESPAL clinical studies but observed in post-marketing environment with risperidone.</p><p><sup>d</sup> Extrapyramidal disorder may occur: Parkinsonism (salivary hypersecretion, musculoskeletal stiffness, parkinsonism, drooling, cogwheel rigidity, bradykinesia, hypokinesia, masked facies, muscle tightness, akinesia, nuchal rigidity, muscle rigidity, parkinsonian gait, and glabellar reflex abnormal, parkinsonian rest tremor), akathisia (akathisia, restlessness, hyperkinesia, and restless leg syndrome), tremor, dyskinesia (dyskinesia, muscle twitching, choreoathetosis, athetosis, and myoclonus), dystonia.</p><p>&nbsp;</p><p>Dystonia includes dystonia, hypertonia, torticollis, muscle contractions involuntary, muscle contracture, blepharospasm, oculogyration, tongue paralysis, facial spasm, laryngospasm, myotonia, opisthotonus, oropharyngeal spasm, pleurothotonus, tongue spasm, and trismus. It should be noted that a broader spectrum of symptoms are included, that do not necessarily have an extrapyramidal origin. <strong>Insomnia</strong> includes: initial insomnia, middle insomnia; <strong>Convulsion</strong> includes: Grand mal convulsion; <strong>Menstrual disorder</strong> includes: Menstruation irregular, oligomenorrhoea; <strong>Oedema</strong> includes: generalised oedema, oedema peripheral, pitting oedema.</p><p><u>&nbsp;</u></p><p><u>Undesirable effects noted with paliperidone formulations</u></p><p>Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compounds (including both the oral and injectable formulations) are relevant to one another. In addition to the above adverse reactions, the following adverse reaction has been noted with the use of paliperidone products and can be expected to occur with RESPAL.</p><p><strong>Cardiac disorders: </strong>Postural orthostatic tachycardia syndrome</p><p><em>Class effects</em></p><p>As with other antipsychotics, very rare cases of QT prolongation have been reported postmarketing with risperidone. Other class-related cardiac effects reported with antipsychotics which prolong QT interval include ventricular arrhythmia, ventricular fibrillation, ventricular tachycardia, sudden death, cardiac arrest and Torsades de Pointes.</p><p><em>Venous thromboembolism</em></p><p>Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotic drugs (frequency unknown).</p><p><em>Weight gain</em></p><p>The proportions of RESPAL and placebo-treated adult patients with schizophrenia meeting a weight gain criterion of &ge; 7% of body weight were compared in a pool of 6- to 8-week, placebo-controlled trials, revealing a statistically significantly greater incidence of weight gain for RESPAL (18%) compared to placebo (9%). In a pool of placebo-controlled 3-week studies in adult patients with acute mania, the incidence of weight increase of &ge; 7% at endpoint was comparable in the RESPAL (2.5%) and placebo (2.4%) groups, and was slightly higher in the active-control group (3.5%).</p><p>In a population of children and adolescents with conduct and other disruptive behaviour disorders, in long-term studies, weight increased by a mean of 7.3 kg after 12 months of treatment. The expected weight gain for normal children between 5-12 years of age is 3 to 5 kg per year. From 12-16 years of age, this magnitude of gaining 3 to 5 kg per year is maintained for girls, while boys gain approximately 5 kg per year.</p><p><u>Additional information on special populations</u></p><p>Adverse drug reactions that were reported with higher incidence in elderly patients with dementia or paediatric patients than in adult populations are described below:</p><p><em>Elderly patients with dementia</em></p><p>Transient ischaemic attack and cerebrovascular accident were ADRs reported in clinical trials with a frequency of 1.4% and 1.5%, respectively, in elderly patients with dementia. In addition, the following ADRs were reported with a frequency &ge;5% in elderly patients with dementia and with at least twice the frequency seen in other adult populations: urinary tract infection, peripheral oedema, lethargy, and cough.</p><p><u>Paediatric population</u></p><p>In general, type of adverse reactions in children is expected to be similar to those observed in adults.</p><p>The following ADRs were reported with a frequency &ge;5% in paediatric patients (5 to 17 years) and with at least twice the frequency seen in clinical trials in adults: somnolence/sedation, fatigue, headache, increased appetite, vomiting, upper respiratory tract infection, nasal congestion, abdominal pain, dizziness, cough, pyrexia, tremor, diarrhoea, and enuresis.</p><p>The effect of long-term risperidone treatment on sexual maturation and height has not been adequately studied (see 4.4, subsection &ldquo;Paediatric population&rdquo;).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>In general, reported signs and symptoms have been those resulting from an exaggeration of the known pharmacological effects of risperidone. These include drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. In overdose, QT-prolongation and convulsions have been reported. Torsade de Pointes has been reported in association with combined overdose of RESPAL and paroxetine.</p><p>In case of acute overdose, the possibility of multiple drug involvement should be considered.</p><p><em>Treatment</em></p><p>Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Gastric lavage (after intubation, if the patient is unconscious) and administration of activated charcoal together with a laxative should be considered only when drug intake was less than one hour before. Cardiovascular monitoring should commence immediately and should include continuous electrocardiographic monitoring to detect possible arrhythmias.</p><p>There is no specific antidote to RESPAL. Therefore, appropriate supportive measures should be instituted. Hypotension and circulatory collapse should be treated with appropriate measures such as intravenous fluids and/or sympathomimetic agents. In case of severe extrapyramidal symptoms, an anticholinergic medicinal product should be administered. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antipsychotics, ATC code: N05AX08</p><p><u>Mechanism of action</u></p><p>Risperidone is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotoninergic 5-HT<sub>2</sub> and dopaminergic D<sub>2</sub> receptors. Risperidone binds also to alpha<sub>1</sub>-adrenergic receptors, and, with lower affinity, to H<sub>1</sub>-histaminergic and alpha<sub>2</sub>-adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although risperidone is a potent D<sub>2</sub> antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.</p><p><u>Pharmacodynamic effects </u></p><p><u>Clinical efficacy</u></p><p><em>Schizophrenia </em></p><p>The efficacy of risperidone in the short-term treatment of schizophrenia was established in four studies, 4- to 8-weeks in duration, which enrolled over 2500 patients who met DSM-IV criteria for schizophrenia. In a 6-week, placebo-controlled trial involving titration of risperidone in doses up to 10 mg/day administered twice daily, risperidone was superior to placebo on the Brief Psychiatric Rating Scale (BPRS) total score. In an 8-week, placebo-controlled trial involving four fixed doses of risperidone (2, 6, 10, and 16 mg/day, administered twice daily), all four risperidone groups were superior to placebo on the Positive and Negative Syndrome Scale (PANSS) total score. In an 8-week, dose comparison trial involving five fixed doses of risperidone (1, 4, 8, 12, and 16 mg/day administered twice-daily), the 4, 8, and 16 mg/day risperidone dose groups were superior to the 1 mg risperidone dose group on PANSS total score. In a 4-week, placebo-controlled dose comparison trial involving two fixed doses of risperidone (4 and 8 mg/day administered once daily), both risperidone dose groups were superior to placebo on several PANSS measures, including total PANSS and a response measure (&gt;20% reduction in PANSS total score). In a longer-term trial, adult outpatients predominantly meeting DSM-IV criteria for schizophrenia and who had been clinically stable for at least 4 weeks on an antipsychotic medicinal product were randomised to risperidone 2 to 8 mg/day or to haloperidol for 1 to 2 years of observation for relapse. Patients receiving risperidone experienced a significantly longer time to relapse over this time period compared to those receiving haloperidol.</p><p>&nbsp;</p><p><em>Manic episodes in bipolar disorder</em></p><p>The efficacy of risperidone monotherapy in the acute treatment of manic episodes associated with bipolar I disorder was demonstrated in three double-blind, placebo-controlled monotherapy studies in approximately 820 patients who had bipolar I disorder, based on DSM-IV criteria. In the three studies, risperidone 1 to 6 mg/day (starting dose 3 mg in two studies and 2 mg in one study) was shown to be significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in total Young Mania Rating Scale (YMRS) score at Week 3. Secondary efficacy outcomes were generally consistent with the primary outcome. The percentage of patients with a decrease of &ge; 50% in total YMRS score from baseline to the 3-week endpoint was significantly higher for risperidone than for placebo. One of the three studies included a haloperidol arm and a 9-week double-blind maintenance phase. Efficacy was maintained throughout the 9-week maintenance treatment period. Change from baseline in total YMRS showed continued improvement and was comparable between risperidone and haloperidol at Week 12.</p><p>The efficacy of risperidone in addition to mood stabilisers in the treatment of acute mania was demonstrated in one of two 3-week double-blind studies in approximately 300 patients who met the DSM-IV criteria for bipolar I disorder. In one 3-week study, risperidone 1 to 6 mg/day starting at 2 mg/day in addition to lithium or valproate was superior to lithium or valproate alone on the pre-specified primary endpoint, i.e., the change from baseline in YMRS total score at Week 3. In a second 3-week study, risperidone 1 to 6 mg/day starting at 2 mg/day, combined with lithium, valproate, or carbamazepine was not superior to lithium, valproate, or carbamazepine alone in the reduction of YMRS total score. A possible explanation for the failure of this study was induction of risperidone and 9-hydroxy-risperidone clearance by carbamazepine, leading to subtherapeutic levels of risperidone and 9-hydroxy-risperidone. When the carbamazepine group was excluded in a post-hoc analysis, risperidone combined with lithium or valproate was superior to lithium or valproate alone in the reduction of YMRS total score.</p><p>&nbsp;</p><p><em>Persistent aggression in dementia</em></p><p>The efficacy of risperidone in the treatment of Behavioural and Psychological Symptoms of Dementia (BPSD), which includes behavioural disturbances, such as aggressiveness, agitation, psychosis, activity, and affective disturbances was demonstrated in three double-blind, placebo-controlled studies in 1150 elderly patients with moderate to severe dementia. One study included fixed risperidone doses of 0.5, 1, and 2 mg/day. Two flexible-dose studies included risperidone dose groups in the range of 0.5 to 4 mg/day and 0.5 to 2 mg/day, respectively. Risperidone showed statistically significant and clinically important effectiveness in treating aggression and less consistently in treating agitation and psychosis in elderly dementia patients (as measured by the Behavioural Pathology in Alzheimer&#39;s Disease Rating Scale [BEHAVE-AD] and the Cohen-Mansfield Agitation Inventory [CMAI]). The treatment effect of risperidone was independent of Mini-Mental State Examination (MMSE) score (and consequently of the severity of dementia); of sedative properties of risperidone; of the presence or absence of psychosis; and of the type of dementia, Alzheimer&#39;s, vascular, or mixed. (See also section 4.4)</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><em>Conduct disorder </em></p><p>The efficacy of risperidone in the short-term treatment of disruptive behaviours was demonstrated in two double-blind placebo-controlled studies in approximately 240 patients 5 to 12 years of age with a DSM-IV diagnosis of disruptive behaviour disorders (DBD) and borderline intellectual functioning or mild or moderate mental retardation/learning disorder. In the two studies, risperidone 0.02 to 0.06 mg/kg/day was significantly superior to placebo on the pre-specified primary endpoint, i.e., the change from baseline in the Conduct Problem subscale of the Nisonger-Child Behaviour Rating Form (N-CBRF) at Week 6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>RESPAL orodispersible tablets and oral solution are bio-equivalent to RESPAL film-coated tablets.</p><p>Risperidone is metabolised to 9-hydroxy-risperidone, which has a similar pharmacological activity to risperidone (see <em>Biotransformation and Elimination</em>).</p><p><u>Absorption</u></p><p>Risperidone is completely absorbed after oral administration, reaching peak plasma concentrations within 1 to 2 hours. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) compared with a solution. The absorption is not affected by food and thus risperidone can be given with or without meals. Steady-state of risperidone is reached within 1 day in most patients. Steady-state of 9-hydroxy-risperidone is reached within 4-5 days of dosing.</p><p><u>Distribution</u></p><p>Risperidone is rapidly distributed. The volume of distribution is 1-2 l/kg. In plasma, risperidone is bound to albumin and alpha<sub>1</sub>-acid glycoprotein. The plasma protein binding of risperidone is 90%, that of 9-hydroxy-risperidone is 77%.</p><p><u>Biotransformation and elimination</u></p><p>Risperidone is metabolised by CYP 2D6 to 9-hydroxy-risperidone, which has a similar pharmacological activity as risperidone. Risperidone plus 9-hydroxy-risperidone form the active antipsychotic fraction. CYP 2D6 is subject to genetic polymorphism. Extensive CYP 2D6 metabolisers convert risperidone rapidly into 9-hydroxy-risperidone, whereas poor CYP 2D6 metabolisers convert it much more slowly. Although extensive metabolisers have lower risperidone and higher 9-hydroxy-risperidone concentrations than poor metabolisers, the pharmacokinetics of risperidone and 9-hydroxy-risperidone combined (i.e., the active antipsychotic fraction), after single and multiple doses, are similar in extensive and poor metabolisers of CYP 2D6.</p><p>Another metabolic pathway of risperidone is N-dealkylation. <em>In vitro</em> studies in human liver microsomes showed that risperidone at clinically relevant concentration does not substantially inhibit the metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP 1A2, CYP 2A6, CYP 2C8/9/10, CYP 2D6, CYP 2E1, CYP 3A4, and CYP 3A5. One week after administration, 70% of the dose is excreted in the urine and 14% in the faeces. In urine, risperidone plus 9-hydroxy-risperidone represent 35-45% of the dose. The remainder is inactive metabolites. After oral administration to psychotic patients, risperidone is eliminated with a half-life of about 3 hours. The elimination half-life of 9-hydroxy-risperidone and of the active antipsychotic fraction is 24 hours.</p><p><u>Linearity/non-linearity</u></p><p>Risperidone plasma concentrations are dose-proportional within the therapeutic dose-range.</p><p><u>Elderly, hepatic and renal impairment</u></p><p>A single-dose PK-study with oral risperidone showed on average 43% higher active antipsychotic fraction plasma concentrations, a 38% longer half-life and a reduced clearance of the active antipsychotic fraction by 30% in the elderly.</p><p>In adults with moderate renal disease the clearance of the active moiety was ~48% of the clearance in young healthy adults. In adults with severe renal disease the clearance of the active moiety was ~31% of the clearance in young healthy adults. The half-life of the active moiety was 16.7 h in young adults, 24.9 h in adults with moderate renal disease (or ~1.5 times as long as in young adults), and 28.8 h in those with severe renal disease (or ~1.7 times as long as in young adults). Risperidone plasma concentrations were normal in patients with liver insufficiency, but the mean free fraction of risperidone in plasma was increased by 37.1%.</p><p>The oral clearance and the elimination half-life of risperidone and of the active moiety in adults with moderate and severe liver impairment were not significantly different from those parameters in young healthy adults.</p><p><u>Paediatric population</u></p><p>The pharmacokinetics of risperidone, 9-hydroxy-risperidone and the active antipsychotic fraction in children are similar to those in adults.</p><p><u>Gender, race and smoking habits</u></p><p>A population pharmacokinetic analysis revealed no apparent effect of gender, race or smoking habits on the pharmacokinetics of risperidone or the active antipsychotic fraction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In (sub)chronic toxicity studies, in which dosing was started in sexually immature rats and dogs, dose-dependent effects were present in male and female genital tract and mammary gland. These effects were related to the increased serum prolactin levels, resulting from the dopamine D<sub>2</sub>-receptor blocking activity of risperidone. In addition, tissue culture studies suggest that cell growth in human breast tumours may be stimulated by prolactin. Risperidone was not teratogenic in rat and rabbit. In rat reproduction studies with risperidone, adverse effects were seen on mating behaviour of the parents, and on the birth weight and survival of the offspring. In rats, intrauterine exposure to risperidone was associated with cognitive deficits in adulthood. Other dopamine antagonists, when administered to pregnant animals, have caused negative effects on learning and motor development in the offspring. In a toxicity study in juvenile rats, increased pup mortality and a delay in physical development was observed. In a 40-week study with juvenile dogs, sexual maturation was delayed. Based on AUC, long bone growth was not affected in dogs at 3.6-times the maximum human exposure in adolescents (1.5 mg/day); while effects on long bones and sexual maturation were observed at 15 times the maximum human exposure in adolescents.</p><p>Risperidone was not genotoxic in a battery of tests. In oral carcinogenicity studies of risperidone in rats and mice, increases in pituitary gland adenomas (mouse), endocrine pancreas adenomas (rat), and mammary gland adenomas (both species) were seen. These tumours can be related to prolonged dopamine D<sub>2</sub> antagonism and hyperprolactinaemia. The relevance of these tumour findings in rodents in terms of human risk is unknown. In vitro and in vivo, animal models show that at high doses risperidone may cause QT interval prolongation, which has been associated with a theoretically increased risk of torsade de pointes in patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzoic acid, Sorbitol liquid 70%, Saccharin Sodium, Citric acid, Purified-water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatible with most types of tea including black tea.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
Shelf life after first opening: 3 months 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at room temperature below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE proof cap and 125 ml amber glass bottle type III</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization
Joswe-medical
P.O. Box 851831 Amman 11185 Jordan 
E-mail: joswe@go.com.jo
www.joswe.com
Tel: +962 6 5859765, +962 6 5728327
Fax: +962 6 5814526, +962 6 5728326

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>